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Abstract 
In response to the opioid epidemic, which has claimed approximately 700,000 lives, a 
national public health emergency was declared in the United States in 2017. The 
epidemic was triggered by medical overprescription under the influence of marketing 
strategies crafted to convince physicians pain was being poorly treated and that fear of 
addiction was unwarranted.  
This study describes the origins of the epidemic through a normative perspective and 
verifies similarities and differences between regulations from Portugal and the United 
States. The aim is to raise awareness of potential contributors to an opioid epidemic in 
Portugal. 
With this purpose, scientific literature and American and Portuguese regulations were 
reviewed. A qualitative study with semi-structured interviews of Portuguese key-
informants within the field of pain management was conducted to address their views 
and perceptions of opioid use in Portugal.  
Medical caution with opioid use was withdrawn and a new practice of treating chronic 
pain unrelated to cancer with opioids was consensually approved without adequate 
empiric evidence. Direct-to-consumer marketing, unregulated sales representatives 
visits and gifts and donations to physicians may have contributed to the conception of 
the epidemic.  
In Portugal, direct-to-consumer marketing is limited and physician-industry relations are 
strictly regulated, nonetheless, opioid use for chronic pain has been approved by 
legislation and opioid sales have increased by 54-fold since 2001. Key-informants agree 
opioid efficacy is limited and preventive measures for opioid overprescription, namely, 
pain management medical education, systematic monitoring of opioid dispensing, and 
information to patients are indicated. 
Key-words: Opioids, epidemic, regulations, chronic pain, direct-to-consumer marketing 
!1
Resumo 
Em resposta à epidemia de opióides foi declarada uma emergência nacional de saúde 
pública nos Estados Unidos em 2017. A epidemia foi desencadeada por excesso de 
prescrição médica e estratégias de marketing criadas para convencer os médicos de que 
a dor estava a ser sub-tratada e que o medo da adição era injustificado. 
Este estudo descreve as origens da epidemia sob uma perspetiva regulamentar dos 
Estados Unidos, verificando semelhanças e diferenças com a situação portuguesa. O 
objetivo é consciencializar para prevenir a possibilidade de uma epidemia similar em 
Portugal. 
Foram analisadas literatura bem como regulamentação americana e portuguesa. Foi 
realizado um estudo qualitativo com entrevistas semi-estruturadas a informantes-chave 
portugueses, especialistas em tratamento da dor, com o objetivo de abordar as suas 
perceções sobre o uso de opióides em Portugal. 
A cautela médica com os opióides foi abandonada e o seu uso para tratar dor crónica 
não-oncológica consensualmente aprovado mesmo sem evidência suficiente. Do ponto 
de vista normativo, visitas de representantes de vendas, marketing direto ao consumidor 
e doações a médicos podem ter contribuído para a conceção da epidemia. 
Em Portugal, o marketing direto ao consumidor é restrito e as relações entre médicos e 
indústria são estritamente regulamentadas. No entanto, desde que o uso de opioides para 
dor crónica foi aprovado em 2001 as vendas destes medicamentos aumentaram 54 
vezes.  
Os informantes-chave concordam que a eficácia do opióide é limitada e medidas 
preventivas para o excesso de prescrição são indicadas, nomeadamente, educação 
especializada, monitoramento e informação ao doente. 
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Foreword 
Four milligrams of intravenous hydromorphone every four hours, a potent opioid 
known by the brand name Dilaudid, was prescribed by the attending physician during 
morning rounds on a summer day in New York City. The year was 2006, and the patient 
was a young black man with sickle cell trait, not the disease. Knowingly, sickle cell 
disease causes serious medical problems such as stroke, blindness, and painful bone 
infarct. Sickle cell trait, on the other hand, is a mutation present in one of two alleles, 
only causing serious health problems rarely, and within the context of severe 
dehydration. This fact did not seem to hold any clinical relevance to the attending 
physician who felt strongly the patient’s pain should be treated aggressively. The 
perplexed patient could not hide his amazement to the treatment plan, to which he 
exclaimed: “I didn’t know this dosage was possible”! The matter of fact was that neither 
did I. 
It was in this opioid permissive scenario that I completed an internal medicine 
internship, neurology residency and neuro-oncology fellowship in the United States 
between 2006 and 2012. The rhetoric du jour was that opioid was safe for treatment of 
any pain and that failing to treat pain was in flagrant violation of the hippocratic oath. 
Physicians were retrained to believe that being overly cautious about prescribing 
opioids was a sign of ineptitude. Educated physicians were not expected to be afraid of 
opioids’ adverse effects. In those days, recommending opioids as the treatment of last 
resort was no longer best practice. 
I did not know then I was witnessing, first hand, the workings of the most deadly drug 
epidemic of American history. I am visited every so often by the memories of 
emergency department consultations for young caucasian women with refractory 
migraine. On one occasion, after days of vigorous treatment with several non-opioid 
medications, the patient desperately asked, “When are you giving me the real 
medicine?”. I was stunned, mostly because it took me so long to notice the underlying 
problem.  
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This dissertation is dedicated to the opioid epidemic that unraveled before my eyes. It is 
an investigative review that patches together what prompted its birth. It is also a 
warning to other countries that indiscriminate use of opioids is not safe and that the cost 
of neglecting this fact is too high.  
!5
Abbreviations 
AAMP - American Academy of Pain Medicine 
al. - line (alínea) 
AMA - American Medical Association 
APED - Associação Portuguesa para o Estudo da Dor 
APS - American Pain Society 
art. - article (artigo)  
CDC - Centers for Disease Control and Prevention 
CFR - Code of Federal Regulation 
CMS - Centers for Medicare and Medicaid Services 
DEA - Drug Enforcement Administration 
DGS - Direção-Geral da Saúde 
EMCDDA - The European Monitoring Centre for Drugs and Drug Addiction 
FDA -  Food and Drug Administration 
FDCA - Federal Food, Drug, and Cosmetic Act 
FSMB - Federation of State Medical Boards 
HHS - United States Department of Health and Human Services 
JC - Joint Commission 
REMS - Risk Evaluation and Mitigation Strategy Program 
SUPPORT - Substance Use-Disorder Prevention that Promotes Opioid Recovery and 
Treatment 
USC - United States Code 
!6
List of Figures 
Figure 1. Age-adjusted drug overdose death rates, by opioid category: United States, 
1999–2016 (Hedegaard, Warner, & Miniño, 2017:p.4)     
Figure 2. All-cause mortality, ages 45–54 for US White non-Hispanics (USW), US 
Hispanics (USH), and six comparison countries: France (FRA), Germany (GER), the 
United Kingdom (UK), Canada (CAN), Australia (AUS), and Sweden (SWE).  
(Case & Deaton, 2015:p.15079)        
Figure 3. Mortality by cause, white non-Hispanics ages 45–54.  
(Case & Deaton, 2015:p.15079)        
Figure 4. Drug overdose death rates, by selected age group: United States, 1999-2016 
(Chen, Hedegaard & Warner 2014: p.2)       
Figure 5. Opioid Overdose Deaths by Gender in the United States: Timeframe 
1999-2017 (KFF, 2017a)         
Figure 6. Prescription opioid overdose hospital admission trend by rurality, 2007 - 2014 
(Mosher et al., 2017:p.926)        
Figure 7. Heroin overdose hospital admission trend by rurality, 2007 - 2014 (Mosher et 
al., 2017:p.926)         
Figure 8. Opioid Overdose Deaths by Race/Ethnicity in the United States: Timeframe 
1999-2017 (KFF, 2017b)         
Figure 9. Map of the United States’ Regions and States (National Geographic, 2019) 30 
Figure 10. Map of the Appalachian Region (ARC, 2019)     
Figure 11. Age-adjusted rates of drug overdose deaths by state, US 2017 (CDC, 2019) 
32 
Figure 12. Maternal Opioid Use Disorder and Neonatal Abstinence Syndrome (NIDA, 
2019)           
Figure 13: Total opioid consumption: Portugal, 2008-2018. (Data obtained from 
Infarmed in 2019)          
Figure 14: Opioid consumption, by type: Portugal, 2000-2018 . (Data obtained from 
Infarmed in 2019)          




In response to the opioid epidemic that plagues the United States, President Trump 
declared a public health emergency on October 16, 2017 (HHS, 2017). A public health 
emergency is declared when an acute threat to the health of a significant number of 
people is acknowledged (WHO, 2008). The declaration allows for regulatory changes to 
be made by public agencies and for the investment of financial and human resources 
(WHO, 2008). It is estimated that over 700,000 people died since 1999 of opioid use 
overdose (CDC, 2018a).  
The epidemic was triggered by medical overprescription of opioids, a practice set in 
motion after the Food and Drug Administration (FDA) approval of Oxycontin, the brand 
for a medication with the active ingredient oxycodone, a long-acting opioid, in 1995 
(deShazo et al., 2018; Kolodny et al., 2015; Jones et al., 2018; Vadivelu et al., 2018, 
Bonnie, Ford, & Phillips, 2017). Oxycontin was marketed as safe, non-addictive, and 
effective, despite the lack of scientific evidence for any of these claims (Von Korff et 
al., 2011; Franklin, 2014).  
In that same year, the American Pain Society (APS)  launched the campaign “5th Vital 
Sign” that established pain should be monitored as closely and frequently as blood 
pressure, heart rate, body temperature and respiratory rate (Campbell, 1996). 
Furthermore, APS indicated that pain, independently from the etiology and duration, 
could be safely treated with opioids (Campbell, 1996).  
The standardisation of opioid use for pain unrelated to cancer have resulted in 
considerable morbidity and mortality associated with the misuse of prescription opioids 
(deShazo et al., 2018; Kolodny et al., 2015; Jones et al., 2018; Vadivelu et al., 2018, 
Bonnie, Ford, & Phillips, 2017; Franklin, 2014).  
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To halt the epidemic, new Federal and State regulations restricting medical prescription 
of opioids were enacted. In addition, the FDA issued a special report with 
recommendations, and, in 2016, the Center for Disease Control and Prevention (CDC) 
crafted a new guideline for opioid use (Dowell, Haegerich & Chou, 2016). The resultant 
emergence of opioid use disorder and the ensuing stricter regulations increased the 
levels of illicit heroin and fentanyl use provoking new waves of opioid related 
epidemics (CDC, 2018a).  
The Fifth Vital Sign campaign reached the Portuguese regulatory framework in 2003 by 
advocacy of the National Plan Against Pain’s commission. In accord with the American 
campaign, it was established by the Direção-Geral da Saúde (DGS), the Portuguese 
public agency responsible for health policies, that the measurement of level of pain 
should be included in the patient’s vital signs sheet (Direcção-Geral da Saúde, 2003).  
In 2008, the DGS released new best practices clinical guidelines permitting the use of 
opioids for pain unrelated to cancer, despite the lack of adequate scientific evidence 
(Direcção-Geral da Saúde, 2008b). 
Following the new guidelines, oxycodone was approved by Infarmed, the Portuguese 
public agency analog to the FDA, in 2011, and, in 2016, increased subsidy by the 
government for prescription of strong opioids to treat chronic pain unrelated to cancer 
was approved (Direcção-Geral da Saúde, 2013; Ordinance nº 329/2016 December, 20). 
Consequently, the use of medical opioids has increased by 70% between 2012 and 2017 
(Reis, 2017). However, this data does not distinguish between treatment for pain related 
or unrelated to cancer.  
The public health epidemic born in the United States was a result of a myriad of events 
that when observed through a normative lens can be summarised by either permissive or 
violated regulatory framework ruling this topic. When both Purdue Pharma and APS 
filed for bankruptcy in 2019, after indictment with criminal charges, it became clear 
fraud played an important part in this tragedy. This dissertation, however, proposes to 
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describe the regulatory framework that allowed for the epidemic outbreak rather than 
delve into matters of corruption.  
The study attempts to indicate normative analogy between American and Portuguese 
regulatory frameworks in order to increase awareness of its strengths and weaknesses 
with regard to opioid use, sales, and marketing.  
Objectives and Scope 
The dissertation’s primary objective is to study the origins of the American opioid 
epidemic through a normative perspective and verify similarities and differences to 
Portuguese regulations for opioid use, sales and marketing, with special regard to 
opioid use for pain unrelated to cancer. The purpose is to raise awareness of possible 
normative weaknesses that could contribute to the emergence of an opioid epidemic in 
Portugal as the one observed in the United States. In order to fulfil this objective the 
following secondary objectives were sought:  
1. Describe the context, factors, and outcomes of the American opioid epidemic; 
2. Identify and describe the regulations for medical use of opioid valid at the outbreak 
of the epidemic in the United States and ensuing regulatory counter-measures; 
3. Identify and describe regulations for medical use of opioid in Portugal; 
4. Explore key informants’ perceptions about opioid medical use and regulatory 
control in Portugal. 
The American public health emergency opioid epidemic is the subject matter of this 
dissertation and the identification of the factors that allowed for the epidemic’s outbreak 
is the starting point to the investigation. A normative perspective is used to describe and 
analyse the documented culprits for the epidemic. The dissertation does not hypothesise 
about unpublished potential culprits nor claims to address every possible one. 
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In broad terms, the scope of this study embraces several topics that could each result in 
independent research within the context of opioid history, epidemiology, public health 
law and policies. In specific terms, the study considers laws and regulations on 
marketing and sales of opioids, restrictions to medical prescription of opioids, 
pharmacovigilance procedures and medical guidelines for opioid use in the United 
States and in Portugal. 
Although some state statutes will be cited, the study is restricted to the description of 
specific federal statutes concerned with opioid use, sales and marketing, therefore, not 
every legal instrument in force and not every law and regulation to that matter. It 
addresses public health and law lato sensu and does not intend to be by any means a 
legal study. This dissertation has a multidisciplinary approach oriented in its essence to 
public health promotion and prevention. 
Structure 
The dissertation begins with the description of background, objectives and scope, 
structure, and methods. It is further divided in two parts: Part I with preliminary 
concepts, epidemiological traits of the epidemic, identified causes for the epidemic, and 
pertinent regulations ruling opioid medical use and sales. Part I ends with an overview 
of opioid use in Portugal and analog regulations for its medical use and sales. 
Part II documents the field work performed for this research; a qualitative study with 
key-informants within the field of pain medicine, Portuguese medical regulatory 
frameworks, and opioid addiction. Key-informants were interviewed to discuss their 
views on opioid medical use, sales, and regulations and its similarities and differences 
to the American practice. Methods, results and discussion for the qualitative study are 
described in detail on Chapter 6. The final conclusions of this dissertation are discussed 
on Chapter 7.  
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Methods 
In order to achieve these objectives, a review, dating back to 1995 and onwards, of book 
chapters, academic articles, medical guidelines, American federal and state regulations, 
Portuguese statutes and guidelines, public hearings, and news media articles, was 
conducted. Pubmed, Scielo, Google Scholar, Web of Science, Jstor, B-on were the 
scientific databases used for the research. A personal visit to the Biblioteca Nacional de 
Portugal was accomplished to ensure a thorough search of published doctoral and 
master studies specific to the use of opioids in Portugal.  
For data regarding the medical opioid use in Portugal, a formal request for data 
concerning the sales of strong opioids was placed to Infarmed. The total number of 
packages of morphine, buprenorphine, hydromorphone, fentanyl, oxycodone, 
oxycodone with naloxone and tapentadol sold over the past 20 years, yearly, was 
provided by Infarmed to the author. This data is described in the text and graphs 
produced by the author on Chapter 5.3.  
After a thorough revision of the epidemic’s causes and major developments a 
descriptive review of components of the federal health law effective at the origin of the 
epidemic in the United States was pursued. The same aspects of the American 
regulations were compared to Portuguese rules alike. The study’s design does not permit 
any conclusion of causation between the laws and the epidemic, instead, it raises 
hypotheses for possible culprits or facilitators. References and citations followed the 
Harvard referencing style. 
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PART I 
Chapter 1. Preliminary Concepts 
This chapter is dedicated to the description of the types of opioids, the history of its use 
in the United States, and the new terminologies implicated within the broad term of 
opioid use disorder. This chapter also provides a summarised review of the definition, 
importance, and research activities of public health law. 
1.1 Opium, Opiates and Opioids 
Opium is an extract of the plant opium poppy, Papaver somniferum, used to treat pain in 
ancient Mesopotamia by Assyrians, Greeks, and Sumerians. (The Editors of 
Encyclopaedia Britannica, 2018a). The extract is composed of organic compounds such 
as morphine, codeine and thebaine (ibid). Analgesics that contain natural derivatives of 
opium are referred to as opiates.  
With the advent of synthetic drugs that act as opium derivatives, a wider term gained 
scientific relevance: opioid. Opioids include any substance, natural, synthetic or semi-
synthetic, endogenous or exogenous, agonist or antagonist, that carry affinity with 
opioid receptors in the central nervous system. (Ciarallo, 2011). 
Opioids are deemed strong or weak based on its potency for relieving pain; stronger 
opioids have higher propensity for misuse and addiction (Koob & Le Moal, 2005). 
Examples of strong opioids are morphine, hydromorphone, hydrocodone, oxycodone, 
fentanyl and methadone. Codeine is considered a weak opioid, as well as tramadol when 
given in lower dosages. Heroin is a strong opioid derived from morphine, no longer 
manufactured for medical use.  
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Codeine and morphine are natural opioids, and hydromorphone, hydrocodone, 
oxycodone are semi-synthetic opioids, or drugs with similar chemical structure to opium 
(ibid). Different from natural and semi-synthetic, synthetic opioids are fully developed 
in laboratory, namely, fentanyl, methadone and tramadol, among others. 
Today, opioids are used in palliative care to treat moderate to severe pain and alleviate 
discomfort and respiratory distress in the dying. Besides the feeling of well being 
elicited by some opioids, side effects such as pruritus, constipation, respiratory 
depression, nausea and vomiting, as well as physical dependence and addiction are 
hallmarks of this class of medication.   
The text will address more frequently the opioids protagonists of the public health 
crisis: the medically prescribed oxycodone and hydrocodone, and less so the illegally 
distributed fentanyl and heroin. The use of methadone, a long acting opioid, used 
predominantly for treatment of opioid dependence, will not be addressed. 
1.2 History of Opioids in America 
Since the American Revolution (1775-1783), opium has circulated American streets to 
relieve the pain of British wounded soldiers (Trickely, 2018). In 1803, morphine was 
isolated from opium by the German scientist Friedrich Sertuner and, in its pure form, 
was found to be ten times more potent. With the advent of the hypodermic needle in 
1853, morphine was used to treat pain and other ailments with unprecedented success 
(Courtwright, 2001). It was used profusely during the American civil war (1861-1865) 
and resulted in approximately 100,000 soldiers addicted to opium (Carroll, 2016).  
Still in the nineteenth century, smoking opium rather than injecting it was introduced in 
the West coast by Chinese immigrants; addicted to opium themselves as a result of the 
Opium Wars waged by British colonialists in China (1839-1860) (Trickely, 2018). 
Chinese immigrants, following the hope and promises provided by the Gold Rush 
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(1848-1855), brought to California opium dens; rooms where people could smoke 
opium. 
The idea of morphine as a relief-all medication transported the demographics of 
morphine use from soldiers to women seeking help to treat menstrual pain and neurosis 
(Courtwright, 2001). By the end of the nineteenth century, physicians were picking up 
on the dangers of morphine addiction and medical journals would frequently offer 
warnings about it (ibid). 
The opioid market was essentially unregulated until the creation of heroin, a derivative 
of morphine distributed under the premise it would be a safer substitute to morphine. 
Heroin was sold by the company Bayer to treat excessive cough and pain (Trickely, 
2018). The practice was slowly picked up by physicians as a dangerous one and as the 
number of prescriptions were already trending down a delayed legislative reform 
arrived in 1914 with the enactment of the Harrison Narcotics Tax Act (Courtwright, 
2015). The act’s goal was to end non-medical use: opium-based drugs were no longer 
sold over-the-counter and record-keeping of sales and dispensing were obligatory (ibid). 
A complete ban of manufacture and sales of heroin arrived in 1924 with the Anti-Heroin 
Act. 
Post-World War II America was marked by a heroin epidemic affecting predominantly 
black communities in urban suburbs. Government action, not only directed towards 
opioids, but also cocaine and crack use, began during the Nixon administration under 
the slogan “War on Drugs” (1971) (The Editors of Encyclopaedia Britannica, 2018b). 
The effort resulted in the creation of the Drug Enforcement Agency (DEA), an agency 
dedicated to the consolidation of intelligence to fight illegal drug trade and use, and 
monitor medical distribution. The campaign reached momentum during the Reagan 
years with greater allocation of resources and the slogan launched by the first-lady 
Nancy Reagan:“Just Say No” (1984), aimed at children in school (The Editors of 
Encyclopaedia Britannica, 2018b). Illegal drug use was considered a criminal offence, 
hence, resources were directed to incarceration and punishment rather than treatment for 
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addiction. As a result, the number for imprisonment increased from 50,000 to 400,000 
between 1980 and 1997 (ibid). 
This dissertation describes how lessons learned by physicians during the nineteenth 
century were discarded under the solace of expert opinion with the term “opiophobia”, 
the medical jargon to delegitimise caution exerted on past experiences. This new opioid 
epidemic emerged with legal medical prescriptions and approval of regulatory public 
agencies, once again with the promise of a less addictive opioid.   
1.3 Opioid Use Disorder: Concepts and Vocabulary 
The opioid epidemic prompted revision of the language used to classify substance use 
disorders with the intent of mitigating the effects of stigma worsened by the use of 
pejorative language (National Academies of Sciences, Engineering, and Medicine, 
2017). Hence, as of the new edition of the Diagnostic and Statistical of Mental 
Disorders launched in 2013, abuse, an expression no longer current, has been 
substituted by the more encompassing term: substance use disorder, or, in this particular 
case, opioid use disorder (APA, 2013).  
Opioid use disorder involves other terminologies: addiction, dependence, tolerance, and 
misuse. Addiction refers to the brain pathology that affects neuronal pathways 
responsible for the control of behaviour, cravings, and the pursuit of reward; 
dependence indicates the presence of withdrawal symptoms without fulfilling the 
dysfunctional psychosocial factors that characterises addiction (ASAM, 2011). Unlike 
addiction and dependence, tolerance designates the growing need for larger doses of the 
drug to achieve its intended effect. The term misuse is reserved to the inadequate use of 
prescribed medication, such as, taking the medication more frequently than indicated or 
for reasons other than the one prescribed. Misuse is a behaviour that precedes addiction 
and is part of the criteria that defines opioid use disorder (ibid). In addition to this 
constellation of terminologies, the definition of opioid use disorder also includes social 
isolation, inability to fulfil obligations, the increasing dominance of the substance over 
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the person’s life, and incapacity to stop using the drug despite negative physical, 
emotional, and social consequences (APA, 2013).  
As a result of  medical overprescribing of opioids, redundant amounts of unused pills 
were available in people’s homes (CDC, 2018; HHS, 2016; Theisen, et al. 2018). The 
use of these pills by friends and family members who have not been prescribed the 
medication is called non-medical opioid use. Furthermore, the expression diversion is 
used to describe the sale of medically prescribed pills in the illegal markets (National 
Academies of Sciences, Engineering, and Medicine, 2017).  
1.4 Public Health Law: Definition and Scope 
Public health is the field concerned with the actions required to protect and promote the 
health of a given population. In 1988, Acheson defined public health as “the art and 
science of preventing disease, prolonging life and promoting health through the 
organized efforts of society” (Acheson, 1988: para.1). The responsibility of ensuring 
welfare and health falls into the government’s duties invested by the people’s power, 
when in a democratic state, under the solace of the rule of law (Gostin, 2007).  
The rule of law establishes that a normative framework composed of laws, regulations 
and public policies shall guide the government’s execution of its duties and powers 
(ibid).  
Normative frameworks are composed of legally binding instruments such as executive 
orders, decrees, statutes, court’s sentences, and non-binding instruments such as best 
practices guidelines and technical standards (World Health Organization, 2017). The 
mainstay difference is that a legally binding instrument is obligatory, hence, if not 
respected, sanctions normally apply. Non-binding legal instruments, expressed often in 
the form of recommendations or resolutions, are essentially guidelines and non-
mandatory norms lacking direct sanction when not observed. 
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In the United States, federal, state, and local governments have jurisdiction to enact 
public health laws (Gostin, 2007). Public health law and policy are influenced by 
government agencies and many areas of civil society, such as education institutions, the 
media, and the private sector (Institute of Medicine, 2011). These sources provide for 
the delimitation of the scope of public health laws. According to Gostin (2007) public 
health law is defined as: 
“… the study of the legal powers and duties of the state to assure the 
conditions for people to be healthy (e.g., to identify, prevent, and ameliorate 
risks to health in the population), and the limitations on the power of the 
state to constrain the autonomy, privacy, liberty, proprietary, or other legally 
protected interests of individuals for protection or promotion of community 
health.” (p.3) 
Public health law, henceforth, must address the tension between protecting society and 
the individual, sometimes in detriment to the individual’s fundamental rights. This 
conflict is evident when the court must decide on, for example, whether to restrict 
liberty and order quarantine, limit privacy and oblige disease notification to a vulnerable 
partner, and limit autonomy by mandating vaccination (Chichevalieva, 2011).  
Still according to Gostin (2007), public health law attends to the correspondence 
between the state and the population, as well as between the state and an individual who 
offers risk to the aforementioned population. Furthermore, it relies on evidence-based 
scientific methods, and is empowered to exert proportional coercion in the name of 
collective welfare (ibid).   
As a tool to advance the promotion of public health, public health law has made 
important achievements; among them smoking bans, safety-belt-use laws, fluoridation 
of community water supplies, regulation of food and prescription drugs, and regulation 
of workplace safety practices are some worth noting (Goodman et al., 2006).   
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In order to verify the impact of law on health, public health law research studies the 
outcomes of legal practices on population health (Burris, 2017). From lawmaking to 
intervention, legal practices, and changes in behavior and environment, public health 
law research aims to measure, monitor, and determine correlation between law and 
health effects (ibid).  
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Chapter 2. The Opioid Epidemic 
The American opioid epidemic has claimed approximately 700,000 lives between 1999 
and 2017 (CDC, 2018a). It is estimated that more than 90 individuals perish daily due to 
opioid overdose (HHS, 2017). In 2017, a nationwide public health emergency, referred 
to as the opioid crisis, was acknowledged by the American government (ibid).  
According to the CDC (2018a), the epidemic is now understood as a continuum of three 
overlapping waves beginning with licitly prescribed opioids followed by two waves of 
illicit opioid use: heroin and fentanyl. The first wave, caused by overly prescribed 
opioid medication for the treatment of chronic pain began in the late 90s (ibid). The 
second and third waves, triggered in 2010 and 2013, respectively, were prompted by the 
rigorous control of opioid prescription in response to the first wave and the resultant 
increase search for illicit cheaper opioids by those who had developed opioid use 
disorder (HHS, 2016).  
In this chapter, an overview of the epidemic will be described with attention to the 
epidemic’s demographics, geographic distribution and the supervening social 
consequences. The effects of parental drug use on newborns and children will be 
reported, as well as the disruption of the American family and the saturation of the 
foster care system.  
A brief summary of what is known at this point about the risk factors for addiction will 
be discussed with special attention to the risk factors induced by the liberalisation of 
opioid use to treat pain unrelated to cancer.  
The chapter ends with an analysis of the epidemic’s financial burden, the diverse 
sources of expenses and the different proposed estimates of the total cost. 
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2.1 Overview 
The United States is home to over 300 million people of which 60.4% declare 
themselves non-hispanic white (U.S. Department of Commerce, 2018). It is estimated 
50 million people are affected by chronic pain, and among those 40% report limitations 
on daily activities secondary to pain (CDC, 2018b). In 2016, 48.5 million individuals 
older than 12 years misused prescription opioids or used illicit heroin (ibid). The 
ensuing result was 63,600 deaths from drug overdose in 2016 and 72,000 in 2017 of 
which more than 60% were attributed to opioids (Stoicea et al., 2019; Hedegaard, 
Warner, & Miniño, 2017).  Approximately 130 Americans die daily due to opioid 
overdose, more than 20 times the number of deaths due to alcohol poisoning, estimated 
at 6 per day (Scholl et al., 2018, Kenny et al., 2015). In a poll performed in 2015, 56% 
of Americans declared encountering someone with opioid use disorder; either who took 
opioid for non-medical use, was addicted, or died from opioid overdose (DiJulio et al., 
2015).  
Opioid consumption in the United States has increased over the past two decades. In 
2009, Americans consumed over 80% of semisynthetic opioids produced in the world, 
namely, oxycodone and hydrocodone (Hauser et al., 2016). In the span of seven years, 
between 2006 and 2012, 76 billion opioid pills were distributed by several 
pharmaceutical companies, most of which are currently being prosecuted for failure to 
report opioid sales to the DEA; this represents on average 248 pills per person in the 
U.S. (Higham, Horwitz & Rich, 2019).  
Over 13 million Americans with private health insurance, aged 18 to 64 years, were 
prescribed opioids for pain unrelated to cancer in 2009 (Liu et al., 2013). Of those, 59% 
were women with a mean age of 43.2 years; one-third of patients had 3 or more opioid 
prescriptions and 12% received prescriptions with more than 90 days supply (ibid). In a 
different study, conducted in 2010, 1.38 million people enrolled to Medicaid (a public 
insurance for those claiming limited income) were treated with opioids: 74% were 
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women, 45.9% of opioid recipients were aged 18-34 years, and 53% received 3 or more 
prescriptions in a year (Mack et al., 2015).  
The rate of fatal drug overdose associated with opioids has increased over time. In 1999, 
the age-adjusted rate, measure that removes the effect of age for comparison, associated 
with prescription opioids, was 1.4 per 100,000, by 2011 the rate climbed to 5.4, and by 
2016 a downturn to 4.4 was observed (Figure 1: Hedegaard, Warner, & Miniño, 2017:p.
4). Following the same upward curve but with later onset, the age-adjusted rate 
overdose due to heroin increased from 0.7 in 1999, to 4.9 in 2016, and for fentanyl 
analogs, also referred to as synthetic opioids other than methadone, the rate went from 
0.3 in 1999 to 6.2 in 2016 (ibid). Between 2013 and 2016 overdose deaths secondary to 
fentanyl increased by 100% every year, climbing from 1,919 to 18,335 (Ducharme, 
2018).   
Federal preliminary data indicates a slight decline at the rate of overdose deaths due to 
opioids during 2018, suggesting the epidemic may have reached its peak and control 
measures are working to some extent (Ducharme, 2019).  
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Figure 1. Age-adjusted drug overdose death rates, by opioid category: United States, 
1999–2016 (Hedegaard, Warner, & Miniño, 2017:p.4)  
2.2 Demographic Pattern 
In 2015, nobel prize winners in Economic Sciences, Anne Case and Angus Deaton, 
published an article that identified a downturn in the life expectancy of white non-
hispanic Americans (Case & Deaton, 2015). The research revealed that if yearly 
mortality rate for whites, aged 45-54, had decreased as expected and as observed in 
other developed countries, five hundred thousand deaths would have been prevented 
between 1999 and 2013 (Figure 2: Case & Deaton, 2015:p.15079). Parallel to the 
increased mortality, the authors observed increased rates of suicide, poisoning, and 
requests for social security insurance for disability (Figure 3: ibid). This observation 
corroborated with the  indiscriminate use of opioid medications noted within the past 
two and a half decades. 
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Figure 2. All-cause mortality, 
ages 45–54 for US White non-
Hispanics (USW), US Hispanics 
(USH), and six comparison 
countr ies : France (FRA), 
Germany (GER), the United 
Kingdom (UK), Canada (CAN), 
Australia (AUS), and Sweden 
(SWE).  
(Case & Deaton, 2015:p.15079)
 
Although the increased mortality was more pronounced among those aged 45-54, a 
similar trend was observed in all age groups between 30 and 54 years (Case & Deaton, 
2015). By 2011, overdose death rates among those aged 15 to 44 years reached the same 
level as the age group 45-54 years (Figure 4: Chen, Hedegaard & Warner 2014: p.2). 
The rate of deaths due to prescription opioids increased by 8.2% for those aged 25-34 
years, 6.2% for the 35-44 age group and 4.9% for the 55-64 age group between 2014 
and 2015 (Rudd et al., 2016). These same age groups demonstrated fatal overdose rate 
reduction due to prescription opioids between 2016 and 2017 (Scholl et al., 2018). This 
improved trend was offset by the increase in overdose deaths due to illicit manufactured 
fentanyl which registered an average ranging from 36 to 50%, affecting all age groups 
(ibid).  
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Figure 3. Mortality by cause, 
white non-Hispanics ages 45–54.  
(Case & Deaton, 2015:p.15079)  
 
The epidemic has affected both men and women, but overdose death rates have been 




Figure 4. Drug overdose death rates, by selected age group: United States, 
1999-2011 (Chen, Hedegaard & Warner 2014: p.2)
Figure 5. Opioid Overdose Deaths by Gender in the United States: 
Timeframe 1999-2017 (KFF, 2017a)
As the epidemic unfurled from prescription opioids to heroin and illicitly manufactured 
fentanyl, a distinctive pattern of unintentional drug overdose mortality taking into 
account age, race, and gender was observed by Jalal et al., (2018). Deaths related to 
heroin and fentanyl analogs cluster in groups of younger white men living in urban 
surroundings, while overdose deaths due to prescription opioids, in decline since 2016, 
prevail among older white women living in rural areas (ibid). Similarly, Mosher et al., 
(2017: p.926) observed hospitalisations due to heroin overdose were more prevalent in 
urban areas, while prescription opioid overdose hospitalisations were higher in rural and 
small urban areas (Figures 6 and 7). In both the urban and rural settings, most 
individuals admitted to the hospital were white: 75-84% urban and 90.13% rural (ibid). 
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Figure 6. Prescription opioid overdose hospital admission trend by 
rurality, 2007 - 2014 (Mosher et al., 2017:p.926) 
 
The opioid epidemic has affected predominantly non-hispanic white Americans (Figure 
8: KFF, 2017b). White patients had better insurance coverage and were more likely to 
receive an opioid prescription from their physician (Hansen & Netherland, 2016). 
During the epidemic’s first wave, the number of deaths among white Americans 
increased from 5,669 in 1999 to 17,927 in 2010 while among blacks and hispanics it 
ranged between 868 and 1380 during the same period (KFF, 2017b). From 2011 
onwards, with the increased availability of illicit heroin and fentanyl, cheaper options 
when compared to the pharmaceutical opioids, mortality rates from opioid overdose 
increased for all races: 48% for whites, 59% for hispanics, and 73% for blacks (ibid). 
Still, in 2017, mortality among whites far exceeded blacks: 37,113 compared to 5,513, 
respectively (ibid). 
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Figure 7. Heroin overdose hospital admission trend by rurality, 
2007 - 2014 (Mosher et al., 2017:p.926) 
 
Medical racial bias is assumed to stem from diverse misguided beliefs: blacks and 
whites are biologically different, minorities are more prone to substance abuse, and 
black people are less sensitive to pain (Santoro et al., 2018). In a study involving 6,170 
emergency department visits between 2006 and 2010, minorities were at least 22% less 
likely to receive treatment for pain, including opioids (Brigham and Women's Hospital, 
2015). In California, a study showed association between opioid overdose and number 
of prescriptions in which both were concentrated in whites with low-income (Friedman 
et al., 2019). 
On the one hand, this discrepancy protected black people and other minorities from the 
opioid epidemic, on the other it revealed medical treatment disparities based on race 
(ibid). Furthermore, Friedman et al., (2019) point out the first wave of this epidemic is 
atypical, for it affects the majority group rather than the minority, commonly the most 
susceptible group.  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Figure 8. Opioid Overdose Deaths by Race/Ethnicity in the United States: 
Timeframe 1999-2017 (KFF, 2017b)
2.3 Geographic Distribution: Regions and States 
The United States is home to fifty states and five main regions: West, Midwest, 
Northeast, Southwest, and Southeast (National Geographic, 2019: Figure 9). An 
increase in fatal overdose due to prescription opioids was initially observed in the 
Southwestern and Appalachian regions (Jalal et al., 2018). The Appalachian region 
encompasses the states along the Appalachian Mountains (Figure 10: ARC, 2019). It 
stretches from southern New York to northern Mississippi harbouring the rural state of 
West Virginia and parts of other 12 states including, Ohio, Maryland, Tennessee, and 
Kentucky. This region is home to counties with the lowest household income in the 
country severely affected by all three waves of the epidemic (ibid).  
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Figure 9. Map of the United States’ Regions and States (National Geographic, 2019)
The epidemic initially expanded to states surrounding Appalachia and to the West 
region, coming to spare no region or state as the epidemic spread (Jalal et al., 2018). 
During the epidemic’s first wave, prescription-opioid-overdose hospital admissions rose 
steadily from 2000 to 2011 in all regions, albeit more pronounced in the South and the 
Midwest; from 2010 onwards, heroin-opioid-overdose hospitalisation climbed in all 
regions, but most remarkably in the Northeast and the Midwest (Unick & Ciccarone, 
2017). 
Throughout the epidemic West Virginia endured the highest rate of overdose deaths and 
received the highest concentration of pills per person calculated at 66.5 (Higham, 
Horwitz & Rich, 2019). In 2006, the majority of fatal overdoses were attributed to non-
medical use and diversion of the prescription opioids (Hall et al., 2008). Ten years later, 
it remains the state with the highest rate of death for all opioids combined as well as for 
illicit manufactured fentanyl in isolation (Scholl et al., 2019). Along with West Virginia, 
the states of Kentucky, South Carolina, Tennessee, and Nevada received the highest 
number of pills per person, ranging from 63.3 to 54.7 (Higham, Horwitz & Rich, 2019). 
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Figure 10. Map of the Appalachian Region 
(ARC, 2019)
Rural areas within these states concentrated an even higher number of pills per person, 
as high as 306 in Norton, Va. (ibid). 
By 2016, the states of Virginia, Alaska, Arizona, Florida, Maryland, Massachusetts, 
Pennsylvania, and South Carolina had utilised their legal authority to declare the opioid 
epidemic a public health emergency. In Virginia, on average 3 people died and 24 
nonfatal overdoses were treated daily in 2016; Massachusetts registered 5 overdose 
deaths per day in 2017 (Macy, 2018). Bostonians were encouraged to carry naloxone 
(the drug that reverses opioid effects) in their backpacks (ibid). To make it ubiquitous it 
is no longer required to have a  prescription to purchase naloxone, which costs on 
average $50 dollars. 
The transition of prescribed opioid to illicit fentanyl has altered the geographic 
distribution of the epidemic to some extent. Fentanyl-induced overdose hotspots mirror 
spots previously concentrated with prescription opioids but is moving towards larger 
metropolitan areas, while heroin, commonly prevalent in urban areas, has found its way 
into smaller counties (Jalal et al., 2018). With the advent of the heroin and illicit 
manufactured fentanyl sub-epidemic, emergency department visits for opioid overdose 
increased in all 5 regions: 69.7% in the Midwest, 40.3% in the West, 21.3% in the 
Northeast, 20.2% in the Southwest, and 14% in the Southeast (Vivolo et al., 2018). 
In 2017, the top five states with the highest rate of fatal overdose were West Virginia, 
Ohio, Pennsylvania, District of Columbia, and Kentucky; age-adjusted rate of drug 
overdose deaths ranged between 57,8 to 37.2 per 100,000 population, and the number of 
deaths ranged from 5,388 in Pennsylvania to 310 in the District of Columbia (Figure 11: 




Figure 11. Age-adjusted rates of drug overdose deaths by state, US 2017 (CDC, 
2019)
2.4 Effects on Newborn and Children  
The incidence of opioid use disorder in women at reproductive-age has been climbing 
steadily resulting in a surge of pregnant women with opioid use disorder, prenatal opioid 
exposure, and neonatal abstinence syndrome (Figure 12: NIDA, 2019). Neonatal 
abstinence syndrome due to opioid withdrawal is a treatable condition which may 
present with excessive crying, fever, sweating, vomiting, rapid breathing, among others. 
Labor among mothers with opioid use disorder have increased by more than four times 
between 1999 and 2014 (ibid). As a result, 32,000 infants are born yearly with neonatal 
abstinence syndrome, the equivalent of 1 for every 15 minutes (ibid; Haight et al. 2018). 
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Figure 12. Maternal Opioid Use Disorder and Neonatal 
Abstinence Syndrome (NIDA,  2019)
Consonant with the established association of opioid use disorder and low-income, the 
proportion of infants delivered with neonatal abstinence is greater among mothers 
covered by Medicaid: 73.7% in 2004 and 82% in 2014 (Winkelman et al. 2018). The 
incidence of neonatal abstinence syndrome increased from 2.8 per 1000 births to 14.4 
per 1000 births within the 10 year-timeframe among mothers covered by Medicaid 
(ibid). 
Prenatal opioid exposed children develop lower cognitive function compared to non-
exposed children (Nygaard, 2015). The onset of discrepant cognitive scores occurs later 
in girls when compared to boys, suggesting the consequences of opioid exposure during 
pregnancy have lasting effects (ibid). 
Notwithstanding the biological consequences of opioid exposure in infants and children, 
problems within the social domains of life are also taking place. As a result of parental 
drug abuse, children are being removed from their parent’s care by social workers 
(Radel et al., 2018). Increase in the opioid prescription rate was associated with a 32% 
rise of foster children in Florida (Quast, Storch, & Yampolskaya, 2018). Nationwide, a 
10% increase of children in foster care due to neglect or death have occurred between 
2012 and 2016, according to the U.S. Department of Health & Human Services (Radel 
et al., 2018). This estimate does not account for orphaned children who are now living 
with their grandparents or other family members.  
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2.5 Risk Factors for Opioid Use Disorder 
Risk factors for addiction are multifactorial. Research studies have indicated genetic 
predisposition is a contributor to the development of opioid use disorder, as well as for 
response to treatment of drug addiction (Kreek et al., 2012). Genetic variability is 
compounded by environmental factors in the social domain, such as educational level, 
family support, level of income, and peer influence (ibid; Blanco & Volkow, 2019). 
Additionally, individuals with mental health disorders, especially with anxiety and 
mood disorders, are at higher risk of developing opioid use disorder (Edlund et al., 
2014; Armaghani et al., 2014).  
The opioid epidemic, however, was marked by the unverified medical practice of 
recommending opioid use for the treatment of chronic pain unrelated to cancer 
(Franklin, 2014). This new medical practice created the growth in demand for opioid 
therapy that was accompanied by a large-scale supply (Bohnert & Ilgen, 2019). The new 
balance of supply and demand of opioids increased the percentage of the population 
exposed to this class of medication for a longer duration allowing for new avenues of 
research into the science of addiction.  
According to a systematic review, rates of addiction among those with chronic pain was 
found to range between 8-12%, and misuse between 21-29%, (Vowles et al., 2015). 
Several studies emerged trying to identify risk factors of opioid misuse among those 
treated for chronic pain unrelated to cancer. 
A prospective cohort study involving veterans with median age of 52 years 
demonstrated the duration of opioid use to be a risk factor for new-onset non-medical 
use of prescription opioids (Barry  et al., 2018). The chances of non-medical use 
increased when opioids were prescribed for 30 to 180 days and for more than 180 days 
at 1.65 and 2 times the adjusted hazard ratio, respectively, when compared to less than 
30 days prescription  (ibid). 
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The same observation was verified in Oregon, where 5% of 536,767 new opioid users, 
excluding cancer patients, became long-term users in the follow-up year of the study 
(Deyo et al., 2017). Number of refills, higher dosage, and long-acting opioids were risk 
factors for transitioning to long-term use, defined as six or more opioid prescriptions 
over the following year (ibid).  
Similarly, patients treated with opioids for pain unrelated to cancer had a significantly 
increased odds of developing opioid use disorder when duration of treatment exceeded 
90 days and when the dosages were higher (Edlund et al., 2014). In comparison to those 
not prescribed opioids, chronic use of opioid with low-dosages had an odds ratio of 
14.92 for developing opioid use disorder, while those using high-dose opioids 
chronically had an odds ratio of 206 (ibid).  
Kaiser Permanente, an American integrated managed care consortium, created an opioid 
registry to identify patients at risk of developing opioid use disorder in Northern 
California. In the span of 4 years, among approximately 400,000 insured patients, 2.7% 
developed opioid misuse and 1,044 had an overdose (Campbell et al., 2018). Younger 
age, concomitant benzodiazepine use, psychiatric comorbidities, higher dosages, and 
prolonged use were identified as risk factors for opioid use disorder (ibid). 
  
In the surgical setting, the treatment for acute pain unrelated to cancer with opioids has 
unleashed yet another cohort of patients with opioid use disorder (Theisen et al., 2018). 
In a cross-sectional study with longitudinal outcome, chronic opioid use was observed 
in 18% of opioid-naive patients who received opioids for pain treatment after major 
spine surgery (Dunn et al., 2018). In those exposed to opioids prior to surgery the 
prevalence of opioid use was above 50% at 12 months (ibid). In a cohort involving over 
1 million patients who underwent surgery, 56% received an opioid prescription post-
operatively; of those, 0.6% were found to have new ICD codes of opioid misuse 
documented in their medical charts (Brat et al., 2018). The rate of misuse increased with 
each additional refill by 44% (ibid). 
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Prescription opioids misuse are a risk factor for heroin use; 80% of new heroin users 
reported non medical use of prescription opioids in the past 12 months (Muhuri, 
Gfroerer & Davies, 2013). Between 2002-2011 approximately 3.6% of those misusing 
prescription opioids reported transition to heroin (ibid). The common pathway for the 
transition to heroin use began with taking prescribed opioids as medically indicated but 
thereafter followed by tolerance, misuse, dependence, and opioid withdrawal symptoms 
(Bonnie, Ford & Phillips, 2017). 
Importantly, the rate of addiction and the relevance of long-term opioid therapy as a risk 
factor may be underestimated by the retrospective nature of most studies dedicated to 
answer this question and by the short duration of follow-up (Busse et al., 2018, Voon, 
Karamouzian & Kerr, 2017). A longitudinal prospective study spanning several years 
has not been performed to date, and therefore, the rate of development of addiction in 
the long-term is unknown (Voon, Karamouzian & Kerr, 2017).  
2.6 The Epidemic’s Economic Cost 
Research dedicated to quantify the economic burden of the opioid epidemic has divided 
the costs into three main areas of expenses: medical care, criminal justice and reduced 
productivity (Birnbaum et al., 2011). In 2007, the total cost of the epidemic was 
approximately $55.7 billion, this estimate has risen to $78.5 in 2013 (ibid; Florence et 
al., 2016).  
Medical care costs which include treatment and medical prescription, as well as 
research expenses and preventive programs accounted for $25 billion in 2007 and $28.9 
in 2013 (Birnbaum et al., 2011; Florence et al., 2016). In 2014 alone, it is estimated 
$563 million dollars were required to cover medicaid costs for the treatment of neonatal 
abstinence syndrome (NIDA, 2019). Approximately $760 million were spent to support 
the bloating foster care system (Radel et al., 2018). Diminished labor force productivity 
resulted in a $25 billion loss and criminal justice costs, which derive from police 
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services, litigations, correctional facilities and property theft summed up to $5.1 billion 
(Birnbaum et al., 2011).  
In a different analysis, Segel et al. (2019) measured the loss in tax revenue due to the 
reduction of the labor force. To their calculation, between the years of 2000 and 2016, 
the state and federal governments failed to collect $11.8 and $26 billion income tax 
revenue, respectively, due to the diminishing workforce (ibid).  
The Council of Economic Advisors of the Executive office of the President of the 
United States used, yet, a different metric to measure the epidemic’s economic cost. One 
which considers the value of life beyond the estimated earnings lost with death, the 
Value of a Statistical Life: the calculation of how much the individual is willing to 
spend to avoid mortality risk factors (The Council of Economic Advisors, 2017). Taking 
into account 33,091 deaths due to opioid overdose, most of them aged between 25 and 
55 years old, and an incremental 24%, estimated to be the amount underreported every 
year, the estimated cost of the opioid epidemic was $431.7 billion, in 2015 (ibid). The 
council’s estimate is more than five-fold higher than the ones reported in previous 
studies. This discrepancy is justified by the different measurements used, the increase in 
overdose deaths along the years, the inclusion of heroin attributed deaths, and the 
accountability of the underreported overdose deaths (ibid).  
The different cost estimates reflect the difficulty in accounting for the multiple layers 
and sources of financial burden cast by the epidemic on public institutions and 
American families. In summary, an epidemic that began within a predominantly rural, 
white, low-income population has spread to all strata of society and the full social, 
economic, and emotional costs are still unraveling.  
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Chapter 3. Contributing Factors to the Opioid Epidemic 
The origins of the current opioid epidemic have been the subject of ample academic 
publications. Four main causes are consensually reported: a concerted movement by 
pharmaceutical industry and medical associations to address the undertreatment of pain, 
increase in medical marketing investment, fraudulent practices by pharmaceutical 
industries, and a slow response to action by public institutions (deShazo et al., 2018; 
Kolodny et al., 2015; Jones et al., 2018; Vadivelu et al., 2018, Bonnie, Ford, & Phillips, 
2017). This chapter will address each of these causes in some detail.  
This chapter will describe the efforts of pain specialists to enhance pain treatment and 
liberalize opioid use through the “pain as the fifth vital sign campaign”. The strategy 
employed by Purdue Pharma to enhance opioid sales is described. To understand the 
American normative framework with regard to medicinal products, the FDA’s duties 
and the federal regulations that enforce medical advertisement, drug approval, labelling, 
and pharmacovigilance is reviewed.   
This chapter will highlight the regulatory weaknesses, modifications, and violations, 
potentially responsible for facilitating the spread of the epidemic. According to a 
position paper by the American Academy of Neurology, the importance of the 
regulatory changes in the 90s allowing for the permissive use of opioid, and the 
endorsement of long-term opioid use for chronic pain unrelated to cancer, a medical 
practice previously considered too risky for misuse and addiction, contributed to the 
epidemic (Franklin, 2014). Other authors point to the regulations that determine the 
oversight of marketing and promotion of drugs as the important culprit (Van Zee, 2009, 
Psaty & Merril, 2017; Bonnie, Ford, & Phillips, 2017).  
Importantly, this analysis does not intend to exhaust all potential contributors to the 
opioid epidemic, and it does not address every regulation pertinent to its conception. It 
is an overview of the main pointed causes responsible for the genesis of the opioid 
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epidemic and the correspondent normative structure that has been either violated or 
inadequate to prevent it.  
3.1 The Fifth Vital Sign Campaign 
In 1995, the APS in partnership with the American Academy of Pain Medicine 
(AAMP), professional membership organisations, launched the campaign, “Pain as the 
Fifth Vital Sign” dedicated to address a perceived consensus among pain specialists that 
pain was being inadequately treated. The Presidential Address, by the sitting president 
Dr. James N. Campbell, laid out the campaign’s premises and goals to improve pain 
management.  
Part of the plan was to adopt a bedside pain evaluation. The evaluation of pain would 
rely on self-reported pain rating scales, numerical, visual, or verbal, which prompted the 
patient to rate the pain between 0 and 10, 0 meaning no pain and 10 the worst pain. 
Nurses should document self-reported pain ratings along with the other vital signs, 
namely, heart rate, blood pressure, respiratory rate, and temperature. In his address, Dr. 
Campbell defended the distinction between chronic and acute pain, and cancer and non-
cancer pain were ambiguous and deleterious for appropriate pain management 
(Campbell, 1996). The statement that followed endorsed the use of opioids for chronic 
pain unrelated to cancer based on the clinical experience of the use of opioids in cancer 
patients who lived longer than expected and derived long-term pain relief (ibid). 
Physician’s cautiousness was decried as secondary to misinformation and regulatory 
control: 
‘Misinformation about what addiction is and myths about liability for 
addiction in patients with pain have not been the only reasons for underuse. 
Fear of regulatory reproach by government is certainly another source of 
concern’ (Campbell, 1996: p.87). 
!40
Ultimately, the campaign mitigated opioid’s adverse side effects by claiming addiction 
is rare, tolerance uncommon, respiratory depression short-lived, and the risk of 
diversion should not be offset by the benefit of relieving pain of those who suffer (Von 
Korff et al., 2011). 
In order to remove the barriers for treatment of chronic pain unrelated to cancer and 
opioid use, the APS unraveled a list of actions: the creation of a foundation funded by 
the industry to serve the public, the assembly of an advocacy group for legislation 
reforms, and the development of an APS Clinical Practice Guidelines Committee to 
mandate treatment reimbursement by government institutions (Campbell, 1996). 
3.1.1 Legislation and Quality Measures Shift Medical Practice 
The concerted effort by APS prompted legislative reform in 1999 when California’s 
legislature passed Assembly Bill 791, which added to the Health and Safety Code that 
pain should be documented in the chart along with the other vital signs; other states 
followed (Baker, 2017). Additionally, on October 31, 2000, the U.S. Congress passed a 
resolution establishing the “Decade of Pain Control and Research”. In 1999 the 
Veteran’s Health Administration, a public health institution dedicated to the provision of 
care for American war veterans, embraced the fifth vital sign campaign providing it with 
added legitimacy nationwide.  
In 2000, the Joint Commission  (JC), a non-profit organisation responsible for the 1
accreditation of healthcare organisations and programs in the United States and 
internationally, adopted the campaign and instituted new quality standards for pain 
evaluation. Healthcare facilities were now obliged to assess pain regularly to maintain 
accreditation (Tompkins et al., 2017).  
In order to guarantee federal healthcare fund reimbursements it is necessary to achieve 
the JC parameters of standard of care or the federal agency’s Centers for Medicare and 
 Previously known as Joint Accreditation Hospital Commission or JAHCO1
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Medicaid Services (CMS), responsible for administering the funds for healthcare for the 
aged and the poor respectively. The CMS used a patient satisfaction survey, part of a 
larger survey, the Hospital Consumer Assessment of Healthcare Providers and Systems, 
to simplify and calculate reimbursements for medical providers (CMS, 2019a). The 
survey is one of the items used by the Hospital Value-Based Purchasing program, a 
program dedicated to the improvement of patient safety through measurement of quality 
of care rather than quantity of services provided (CMS, 2019b). The hospitals receive 
their payments based on several quality measures of performance included in the 
survey. Between 2006 and 2016, the assessment of patient satisfaction related to pain 
management was one of the items used to define federal reward bonuses (Adams, 
Bledsoe, & Armstrong, 2016). The Fifth Vital Sign campaign premise was inserted into 
the intricate healthcare evaluation process and became a determinant factor for financial 
reimbursement. 
Early evaluations in the setting of acute postoperative pain control showed that higher 
doses of morphine were prescribed between 2000-2002 and the increased use of opioids 
in that setting did not result in higher rates of increased length of stay, naloxone use, or 
nausea (Frasco et al., 2005). However, questions surrounding the safety of numerical 
scales guiding pain treatment emerged in 2005 when Villa et al. (2005) disclosed the 
incidence of opioid oversedation increased from 11 to 24.5 per 100,000 patients along 
with sentinel events of fatal respiratory depression. A decade after the launch of the 
Fifth Vital Sign campaign, the cost of patient satisfaction was measured by the study of 
Fenton et al. (2012), composed of a prospective cohort of 51,946 respondents to the 
national Medical Expenditure Panel Survey between 2000-2007. The results indicated 
that highest patient satisfaction scores were associated with an increase in hospital 
admissions, higher prescription drug expenditures, and increased mortality (ibid). 
Once embraced by the JC and the CMS, hospital’s caution with abiding to the 
campaign’s guidelines could translate into less federal reimbursement, an apprehension 
only abated by diligent respect to the newly instated requirements. While measuring 
pain as a fifth vital sign became an obligation in many states once enacted by legislative 
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bodies, the recommendations made by APS were non-binding, and, therefore, did not 
oblige physicians to treat pain with opioids. Indirectly, however, it pushed hospitals to 
train the physicians and nurses to be more aggressive with pain treatment and made it 
easier and less concerning for physicians to prescribe opioids in the inpatient and 
outpatient setting. 
By 2009, the JC acknowledged the relationship between numerical pain scale and 
opioid addiction prompting removal of the statement that pain should be assessed in all 
patients, and in 2011 reiterated that other strategies for pain relief despite opioid 
addiction should be sought (Baker, 2017). In November 2016, the CMS ruled that the 
pain management survey be removed from the scoring system used by the Hospital 
Value-Based Purchasing Program (CMS, 2016). In 2018, a new type of survey 
dedicated to pain communication rather than management was approved (Thompson, 
2017).  
Along with the JC and the CMS, other medical associations that had previously 
embraced the fifth vital sign campaign have withdrawn their support. Current efforts to 
improve pain management and treatment are directed to the refinement of the 
unidimensional aspect of the pain scale to a multidimensional type that includes 
assessment of function debilitated by pain as well as psychosocial risk factors that might 
alter self-reporting levels of pain (Baker, 2017).  
The Fifth Vital Sign campaign’s changes to the medical practice of pain treatment and 
the opioid use were twofold: instituted a simplistic but systematic pain assessment that 
prompted aggressive treatment with opioids for hospitalised patients and endorsed the 
empirically unproved treatment of chronic pain unrelated to cancer with opioids based 
on expert consensus alone. 
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3.1.2 FSMB, DEA, and Opioid Prescription 
Parallel to the efforts drawn to measure pain frequently and to treat it with opioids, 
advocacy groups, medical associations and pharmaceutical companies, succeeded in 
softening the guidelines and regulations of medical prescription for opioids under the 
supervision of the DEA and the Federation of State Medical Boards (FSMB), a non-
profit organisation that assists state medical boards with licensing and regulatory 
overview of physicians (Franklin, 2014).  
Signed into law in 1971, the Controlled Substances Act is the federal statute that 
determines the regulation of production, distribution, and possession of drugs with risk 
for abuse (Controlled Substances Act Title 21 Ch. 13 §811). The act classifies five 
different schedules of drugs based on its potential for abuse; schedule I drugs have the 
highest potential and schedule V the lowest. Schedule I drugs are not indicated for 
medical use in any circumstance and schedule II drugs are allowed with major 
restrictions. Drugs classified between schedule III and schedule V are accepted for 
medical use. Most opioids are considered schedule II drugs, the exceptions being 
heroin, a schedule I drug, and buprenorphine and low-dose codeine derivatives, 
schedule III.  
In 1973, the DEA was created to enforce the Controlled Substance Act (supra 1.2). The 
DEA’s duties include, among others, fighting illegal drug trade and monitoring illegal 
sales of licit drugs. To that end physicians, pharmacists, and other healthcare 
professionals must request a licensing number to prescribe or sell controlled substances. 
By this mechanism, the DEA monitors the amount of controlled substances prescribed 
by healthcare professionals.  
Both federal and state legislative bodies are authorised to regulate the use of controlled 
substances (Hill, 1996). The comprehension of the regulations is muddled by the 
heterogeneous policies advocated by the different state medical boards (ibid). A survey 
conducted by the APS in the early nineties revealed physicians refrained from 
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prescribing opioids for chronic pain management due to fear of regulatory control (Turk 
& Brody, 1992). Some states requested specialist consultation for patients with 
substance abuse problems in need of treatment with opioids, while others indicated the 
necessity of chart documentation that alternate treatment methods were attempted prior 
to opioid use (Joranson et al., 2002).  
In order to create consensus and mitigate the policies’ heterogeneity, eleven workshops 
about pain management, attended by nation-wide state board members, were sponsored 
by the FSMB and the Pain Policy Study Group, a research program at the University of 
Wisconsin that received funding from Purdue Pharma (infra 3.2). The workshop’s 
educational material included debunking the “exaggerated fear of addiction and 
concerns about regulatory scrutiny” (Joranson et al., 2002:p.140). 
In 1998, the FSMB developed the “Model Guidelines for the Use of Controlled 
substances for the Treatment of Pain” (ibid). The Model, a non-legally binding 
instrument, was endorsed by the DEA to reassure physicians that regulatory control over 
the amount of opioid prescribed would allow for appropriate access to those in pain 
(ibid). The goal was to create a uniform pain management policy among medical state 
boards. 
The model’s goal was to quell physician’s fear of regulatory sanctions while prescribing 
opioids by allowing unlimited number of prescriptions (Franklin, 2014). The Model’s 
policies were adopted by several states and, henceforth, regulatory changes loosening 
the restrictions for opioid prescriptions were embedded into legislature (ibid). For 
example, in 1999, Washington State’s administrative code, a legally binding instrument, 
stated: “No disciplinary action will be taken against a practitioner based solely on the 
quantity and/or frequency of opioids prescribed” (Franklin et al., 2015:p.464). 
FSMB guidelines, along with the aforementioned changes into Washington State’s 
administrative codes have since changed and been updated to reflect a more 
conservative use of opioids (ibid). 
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A concerted action taken by advocacy groups, medical associations, pain management 
experts, and the industry resulted in recommendations and laws that changed the 
landscape of pain evaluation and management. A permissive opioid scenario was 
created and persisted for a few years before step-by-step, both legislative and non-
legislative instruments were reviewed in order to halt the epidemic (infra 4.2).   
3.2 Purdue Pharma’s Marketing Strategy 
The opioid epidemic has direct ties to the pharmaceutical industry and medical 
associations fostered by the unprecedented investment in professional marketing (Van 
Zee, 2009; Patsy & Merril, 2017). The responsibility for triggering the epidemic has 
been attributed to the drug OxyContin, a long-acting opioid analgesic launched into the 
market by the manufacturer Purdue Pharma in 1995 (deShazo et al., 2018; Kolodny et 
al., 2015; Jones et al., 2018; Vadivelu et al., 2018, Bonnie, Ford, & Phillips, 2017). 
Purdue Pharma is an American pharmaceutical company owned exclusively by the 
Sackler family. Arthur Sackler, the eldest of three brothers and a trained psychiatrist, 
obtained his wealth while innovating pharmaceutical marketing strategies in the 1960s, 
namely by extending doctors favours and gifts, funding experts to endorse a drug, and 
broadening the drug’s treatment indications (Macy, 2018; Keefe, 2017; deShazo et al., 
2018). Arthur’s major pharmaceutical marketing success involved the anxiolytics, 
Librium (chlordiazepoxide) and Valium (diazepam), with reported record sales of more 
than a hundred million prescriptions in 1973 (Keefe, 2017).  
In 1952, Arthur and his younger brothers, Mortimer and Raymond, bought a small 
pharmaceutical company called Purdue Frederick following the acquisition of a medical 
advertising agency and a medical news magazine (Macy, 2018; Keefe, 2017). Ten years 
later, Arthur was summoned by the Senate to testify regarding the integrated operation 
they owned, from drug production to drug marketing and sales, but the hearing 
amounted to no consequences (Keefe, 2017). The family business thrived and after 
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Arthur’s death in 1987, the brothers bought his shares and changed the company’s name 
to Purdue Pharma. OxyContin was soon to be released under the leadership of 
Raymond’s son Richard, a trained physician as his father and uncles. 
OxyContin contains the semi-synthetic opioid called oxycodone and a thin layer of 
coating that allows for controlled drug absorption. The launch of OxyContin came soon 
after the company lost its patent for MsContin, an opioid analgesic marketed in 1980 
with the same type of coating allowing for the controlled release every 12 hours, but 
with morphine instead of oxycodone as the active ingredient.  
Different from MsContin, the marketing campaign for OxyContin was crafted to rebuke 
the dangers of opioids’ side effects, specially among physicians (Kolodny et al., 2015; 
Jones et al., 2018). The strategy was orchestrated based on results observed in focus 
groups studies, sponsored by the company, which revealed the biggest obstacle for 
prescription was the fear of the potential for abuse (Keefe, 2017). Efforts were drawn to 
inculcate into the medical community’s practice that previous knowledge about opioid 
addiction was exaggerated and outdated, called by some “opiophobia” an understanding 
that led, according to some pain specialists, to the undertreatment of pain (Kolodny et 
al., 2015; Vadivelu, et al. 2018; Jones et al., 2018). The symptoms of withdrawal were 
either not discussed or attributed to the fabricated concept of “pseudo-addiction” an idea 
that claims withdrawal symptoms are due to unrelieved pain that requires larger doses 
of opioid instead of its tapering (Kolodny et al., 2015).  
According to pain specialists employed by Purdue Pharma, opioid use required 
destigmatisation. To that end, sales representatives were taught in three weeks training 
sessions how to reassure physicians the rate of addiction was low and argue its 
indications should be broadened (ibid). While MsContin was used primarily in palliative 
care and cancer pain, OxyContin was endorsed by the pharmaceutical companies, with 
the increasing support of medical associations, as safe for acute or chronic pain 
unrelated to cancer including arthritis, back pain, sports injuries, and fibromyalgia. The 
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plan was to extend the indications beyond cancer pain despite no good scientific 
evidence of effectiveness or safety (Jones et al., 2018). 
The marketing strategies were diverse, among them ads in medical journals, distribution 
of questionable scientific literature to medical offices, hiring of prominent physicians to 
endorse the drug, fraudulent scientific studies performed by the company, sponsoring of 
websites concerning chronic pain, distribution of objects with the brand’s name, 
promotion of videos with patients’ and physicians’ testimonials, false claims of 
percentage of addiction, distribution of financial resources to continuing medical 
education and state medical boards, and distribution of OxyContin coupons for free 
prescriptions 30 days worth (deShazo et al., 2018) .  
The campaign financed by Purdue sponsored the APS, AAPM, FSMB, JC, and patient 
advocacy groups to legitimise and provide credibility to an opioid permissive new 
culture (Kolodny et al., 2015). The development of guidelines endorsing opioids to treat 
chronic pain unrelated to cancer, solely based on expert consensus, was a collaboration 
between the AAPM, APS, and paid physicians by Purdue (deShazo et al., 2018). 
According to Dr. Andrew Kolodny, the co-director of the Opioid Policy Research 
Collaborative, the result of the marketing strategy employed by Purdue Pharma resulted 
in a false idea that prescribing opioids for any pain was safe (Kolodny et al., 2015). A 
permissive attitude was re-inaugurated, a rebirth from the pre-heroin era (supra 1.2). 
In 2001, Purdue invested 200 million dollars with marketing expenses, the next year the 
number of prescriptions increased from 670,000 to 6.2 million prescriptions (Van Zee, 
2009; deShazo et al., 2018; Jones et al., 2018). The notable increase in the number of 
prescriptions was the result of the employed marketing strategy, resulting in legal 
medical overprescription (Van Zee, 2009). Overprescription by physicians led to the 
creation of pill mills. A pill mill is a medical office or pharmacy that sells narcotics 
illegally for non-medical purposes. Through a prescriber profiling company owned by 
the Sackler family, Purdue Pharma’s sales representatives knew which physicians were 
more prone to prescribe opioids, and therefore better sales targets (Patsy & Merril, 
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2017; Keefe, 2017). With that data in hand, Purdue was also aware of the existing pill 
mills and its locations, but opted not to alert authorities (Keefe, 2017).  
Within five years, the company’s revenue was 1 billion dollars a year and sales 
representatives shared 40 million dollars in bonuses in 2001 alone (ibid). When 
confronted with the increased rate of overdose deaths Purdue would respond by 
demeaning the addicted as “junkies” and condemning them for tainting their product 
capable of relieving people’s pain (ibid). 
Signs of abuse emerged within the first year of sales in small towns in central 
Appalachia (Macy, 2018). Reportedly, pills were being grounded and snorted in order to 
surpass the coating providing for the time release mechanism (ibid). In 2010, right about 
when the patent was about to expire, a new abuse-deterrent formulation for Oxycontin, 
one which prevented grounding and snorting of the pill, was approved.  
As the epidemic grew stronger, the institutions previously permissive to the opioid surge 
began voicing concern. In 2003, DEA publicly denounced Purdue for deliberately 
minimising the risk of addiction. In that same year, the FDA signed a warning letter 
addressed to Purdue’s executive vice president referring to two medical journal 
advertisements published in the Journal of the American Medical Association in 2002 
affirming it omitted minimal safety information, minimised the risks associated to 
OxyContin, and recommended the drug to medical conditions with no substantiated 
clinical evidence. The letter concludes by requesting Purdue Pharma to immediately 
stop disseminating inaccurate information (Van Zee, 2009) 
Purdue Pharma did not fully comply with the FDA’s request and in 2007 lost its first 
federal lawsuit pleading guilty to criminal charges for misleading society with 
fraudulent misbranding (Meier, 2007). The company and three of its executives paid a 
total of $634 million in fines to federal and state agencies, and payments to settle civil 
litigations (ibid). In March 2019, Purdue Pharma settled another lawsuit based on 
charges against deceptive marketing, this time in Oklahoma, for $270 million. In 
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January 2019, the plaintiff Attorney General Maura Healey, of the state of 
Massachusetts, filed a lawsuit claiming ‘Purdue Pharma created the epidemic and 
profited from it through a web of illegal deceit’, furthermore, ‘Purdue misled them to 
use higher and more dangerous doses’, and , ‘Purdue deceived them to stay on its drugs 
for longer and more harmful periods of time’ (Healey, 2019: p.2). Along with 
Massachusetts, a total of 44 states, and more than 1,600 cities and counties have filed a 
similar lawsuit against Purdue. The company filed for bankruptcy in 2019. 
Medical marketing tools were misused by Purdue Pharma and other pharmaceutical 
companies. Deceptive information with regard to the safety and effectiveness of the 
drug were endorsed by medical associations and pain medical experts with the financial 
support of Purdue Pharma. The permission of general direct-to consumer advertising, 
physician and associations gifts and donations, and free samples for patients and 
physicians opened the door to more abrasive and, at times, fraudulent activities.  
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Chapter 4. The FDA 
The United States FDA is a federal agency responsible for preserving public health 
safety by regulating foods, drugs, vaccines, blood products, medical devices, radioactive 
equipment, cosmetics, veterinary products, and tobacco (FDA, 2018).   
The FDA was conceived in 1930 from the Bureau of Chemistry within the Department 
of Agriculture created in 1906 to enforce the Pure Food and Drugs Act; a law which 
prohibited the commerce of misbranded and adulterated foods, drinks, and drugs. At the 
time, manufacturers were not obliged to submit any information to the Bureau prior to 
marketing their products. In 1912, the law was amended to prohibit fraudulent claims 
about drugs, but establishing intent was hard (ibid).  
As a result of 107 deaths secondary to the ingestion of toxic ingredients found in the 
Elixir sulfanilamide, a new law was enacted in 1938: the Federal Food, Drug, and 
Cosmetic Act (FDCA) The FDCA, described on Chapter 9 of the United States Code 
(USC) under Title 21 named Food and Drugs, repealed the Pure Food and Drugs Act 
and expanded the FDA authority on matters of safety (FDCA Title 21 USC Ch.9 §321 to 
399i). This act requires manufacturers to apply for approval and provide evidence that a 
drug is safe. Further progress in drug regulation came in 1962 when the FDCA was 
amended by the Kefauver-Harris Act that called for evidence of the drug’s effectiveness 
in addition to safety information (FDA, 2018; FDCA Title 21 USC Ch.9 §355). 
In this chapter, federal laws and regulations of the USC and the Code of Federal 
Regulation (CFR), with respect to advertisement, drug approval, labelling and 
pharmacovigilance will be discussed. The USC is the compilation of federal laws and 
the CFR is the official collection of rules determined by government agencies. The 
normative framework of these topics are enforced by primarily, but not exclusively, 
Title 21 of the USC, Title 21 of the CFR, and state legislation.  
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4.1 Advertisement, Drug Approval, Labelling and Pharmacovigilance 
Medical advertisement in the United States allows direct-to-consumer and professional 
advertising of prescription drugs, disease awareness campaigns, and the advertisement 
of laboratory tests and health services (Schwartz & Woloshin, 2019). Between 1997 and 
2016, spending on advertisements to medical professionals increased from $15.6 billion 
to $20.3 billion, but decreased in the percentage of overall marketing spending from 
88% to 68% (ibid). This decline is due, in part, to the steeper increase in spending on 
direct-to-consumer advertising which rose from $2.1 billion in 1997 to $9.6 billion in 
2016 (ibid). 
4.1.1 Medical Advertisement 
In the United States, direct-to-consumer advertising is permitted for both prescription 
and over-the-counter drugs (FDCA Title 21 USC §352; Title 21 CFR §202.1). 
Advertisement to the general public may be in the form of television commercials or 
published in print. It was approved into law in 1985 but was only widely used after 
1997 when the FDA became more lenient towards the required obligatory list of side-
effects reported by manufacturers (WHO, 2019).  
Besides the United States, direct-to-consumer advertising is only allowed in New 
Zealand and has been criticised for increasing consumption of expensive drugs, 
encouraging off-label drug use, and misinforming the public (ibid). In 2015, the AMA 
called for a ban of direct-to-consumer ads with the purpose of curbing the demand of 
costly treatments that aren’t necessarily clinically superior (AMA, 2019a). To this date, 
the ban has not been adopted.   
In most cases, the industry is required to inform the FDA of advertisement content only 
after its distribution (FDCA Title 21 USC §352). Misleading information is illegal, and 
when detected by the FDA a warning letter is sent for correction prior to pursuing legal 
action (Title 21 CFR §202.1). Penalties and sanctions may apply.  
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Professional advertising, different from the direct-to-consumer ads, is dedicated to 
physicians and other healthcare workers.(Schwartz & Woloshin, 2019). As a rule, 
advertisement may not be false or misleading; for example, benefits and side effects 
must be equally informed (FDCA Title 21 USC §352; Title 21 CFR §202.1). 
Comparative statements are allowed when two or more randomised trials have 
demonstrated the drug’s superiority (Title 21 CFR §202.1(e)). In 2016, less than half of 
the promotional material for new drugs or old drugs with new indications were 
reviewed by the FDA (Schwartz & Woloshin, 2019). 
With regard to gifts and donations, federal statute forbids physicians to accept bribes in 
exchange for federal health care program reimbursements (Anti-Kickback Statute Title 
42 USC §1320). However, this statute does not render gifts and donations illegal for 
there are exceptions that allow for this activity, such as, other types of remuneration and 
consulting services (Kracov & Davar, 2019). Sales representatives’ visits are, 
essentially, not regulated by federal law. Non-binding ethics code by the AMA and the 
Pharmaceutical Research and Manufacturers of America stipulate limitations to both 
gifts and sales representatives visits to physicians (AMA, 2019b; PhRMA, 2019). State 
legislation and hospital policies may legislate to restrict these practices (Kracov & 
Davar, 2019). In 2010, the Physician Payment Sunshine Act was enacted to promote 
transparency of the gifts offered to healthcare providers (infra 4.2.4).  
Continued medical education deemed independent from promotional activity is not 
regulated by the federal government (FDA, 1997). Sponsorship by manufacturers for 
educational activities is permitted and should follow the FDA non-binding guidance for 
the industry, issued in 1997, that stipulates what determines independent scientific and 
educational activities. The factors taken in consideration include: development of 
content and choice of speakers, disclosures regarding program funding and speaker’s 
conflict of interests, relationship between activity organizer and the manufacturer, and 
audience selection (ibid). The FDA may be warned to investigate when these 
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considerations have been disregarded, however, the lack of regulation prevents legal 
proceedings (ibid). 
Physicians are allowed to receive free samples of drugs by means of a written request 
(Title 21 CFR §203.30(a)). Manufacturers are responsible for keeping record of an 
inventory of distribution (Title 21 CFR §203.30(a); FDCA Title 21 USC §503). In 2010, 
with the enactment of the Affordable Care Act, manufacturers must inform the FDA of 
the inventory (Affordable Care Act §6004). 
4.1.2 Drug Approval 
In order to guarantee the public’s health and determine the drug’s safety and 
effectiveness, the FDA monitors the investigation of new or reformulated drugs, 
cosmetics, and medical devices (Bonnie, Ford, & Phillips, 2017). The approval of new 
drugs are submitted by the manufacturers through a New Drug Application form after 
successful completion of human studies (Title 21 CFR §315.50). Clinical studies are 
divided in phases: phase I trials are dedicated to determining the drug’s 
pharmacokinetics and safety profile in a small pool of patients; phase II and III trials 
aim to verify safety in larger cohorts and to study effectiveness. While phase II trials are 
single-arm studies with a small cohort, phase III trials are randomised studies with a 
larger cohort defined by statistical measures to verify for the significance of the drug’s 
effectiveness. These data are submitted to the FDA and analysed by a multidisciplinary 
team that includes professionals within the field of medicine, pharmacology, and 
toxicology (ibid).  
Up to 1997, two phase III trials were needed to allow for the approval of a new drug, 
however, the Food and Drug Administration Modernization Act amended the FDCA and 
decreased the requirement to only one study in certain conditions (Bonnie, Ford, & 
Phillips, 2017). Currently, approximately one-third of approved novel therapeutics meet 
these conditions (Downing et al., 2014). A new indication attributed to a previously 
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approved drug requires a supplemental new drug application that can undergo a regular 
or abbreviated approval pathway (FDCA Title 21 USC §355 (j)).  
In addition to the analysis of the studies’ results, the FDA devises a qualitative benefit-
risk assessment, occasionally with the help of an advisory committee composed of 
experts and stakeholders such as consumers and industry representatives, albeit the 
latter is not allowed to vote (Bonnie, Ford, & Phillips, 2017).  
In 1995, OxyContin was approved by an abbreviated pathway indicated for 
reformulated drugs that relies on previously published scientific studies of safety and 
effectiveness (Bonnie, Ford, and Phillips, 2017; FDCA Title 21 USC §505(b)(2)). 
Dosages of 10, 20, and 40 mg were initially approved to be taken at an interval of 12/12 
hours for the management of moderate to severe pain. Reportedly, the FDA’s medical 
review officer observed no evidence of superior efficacy of OxyContin when compared 
to immediate-release oxycodone, the only advantage being increased dosage intervals 
(Van Zee, 2009). However, proving a drug is more effective than another is not 
necessary for the FDA to establish the drug has substantial evidence of efficacy for 
approval (Bonnie, Ford, & Phillips, 2017). 
The following year, a bio-equivalency study report was submitted for the approval of 
higher dosages, 80 and 160 mg, indicated for patients tolerant to opioids. The dosages 
were approved despite the fact that by the company’s own results, 68% of the 
oxycodone was immediately available when the tablet was crushed, an amount 
potentially fatal to the opioid-naive patient (Van Zee, 2009). 
4.1.3 Labelling 
Label is defined as the information contained in the box holding the product or the 
product itself (FDCA Title 21 USC §321(m)). As is the case with advertisement, 
labelling may not be misleading in accordance with the 1966 Fair Packaging and 
Labeling Act, further amended by the FDCA (ibid §321(n)). The FDA reviews the 
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manufacturer’s label with the proposed drug’s indications, instructions, and potential 
adverse effects, once the drug is approved for distribution (Bonnie, Ford, & Phillips, 
2017).  
In the case of OxyContin, the FDA approved the manufacturer’s proposed label stating 
iatrogenic addiction was very rare when opioids are prescribed appropriately, and 
allowed for the statement that delayed absorption was believed to reduce the risk of 
abuse (Van Zee, 2009). The FDA examiner who oversaw the new drug approval was Dr. 
Curtis Wright, who within two years was employed by Purdue, a practice allowed by 
federal ethics rules which states a former senior official is allowed to join corporate 
boards after one year away from a public agency (Keefe, 2017; Kaplan, 2019). 
The dosage interval of every 12 hours was the drug’s main selling point and argument to 
guarantee insurance reimbursements when confronted by competitive opioids with 
lesser cost (Van Zee, 2009). Neither statements, that iatrogenic addiction is rare and that 
delayed absorption reduce the risk of addiction, were supported by evidence-based 
research (Bonnie, Ford, & Phillips, 2017). 
Notwithstanding, when the FDA understands misleading or false information is 
disclosed by the label or drug advertising, it sends the manufacturer a warning letter, 
requiring revision and action upon the issues listed. Despite the expansion of medical 
marketing over the past decade, the number of violation letters for prescription drug 
advertisement decreased from 156 to 11 during the same period (Schwartz & Woloshin, 
2019). Ultimately, the FDA may sue the company for false claims and retrieve payments 
for prescriptions paid by Medicare or Medicaid (Bonnie, Ford, & Phillips, 2017).  
In 2001, in response to the FDA warning letter, OxyContin’s label was corrected to 
clarify the incidence of addiction in patients with chronic pain was unknown, and the 
assumption of reduced risk of abuse was removed (ibid). 
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4.1.4 Pharmacovigilance 
Pharmacovigilance is the activity of observing for adverse events undetected during the 
clinical trials once the drug is distributed to the general public. The magnitude of 
public’s exposure to the drug amplifies exponentially once the drug is approved for sale. 
New adverse reactions not observed during clinical trials may surface to light, rendering 
it necessary for continued post marketing surveillance of adverse reactions. Adverse 
drug experience is considered as life-threatening, serious, or unexpected (Title 21 CFR 
§314.80(a)). 
It is the manufacturer’s responsibility to review all spontaneous notifications of adverse 
effects from any source, national or international (ibid §314.80(b)); this information 
must be submitted to the FDA at quarterly intervals for three years followed, and 
annually thereafter (ibid §314.80(b)(i)). Adverse event reports submitted by healthcare 
professionals, patients, and drug manufacturers are stored in the FDA’s Adverse Event 
Reporting System database. Pharmacovigilance post-marketing studies are conducted 
by the manufacturers periodically, but not obligatorily (Bonnie, Ford, & Phillips, 2017).  
According to Nachlis (2018), FDA regulations provide for strong influence prior to 
drug’s approval and distribution, and weak oversight of post-marketing and 
pharmacovigilance activities. Between 2004 and 2016, 784,517 adverse events related 
to opioids were reported to the FDA's Adverse Event Reporting System database, 
among those, 158,181 (20%) were attributed to oxycodone (Veronin et al., 2019). 
4.2 Outline of the Public Health Emergency Countermeasures 
Public authorities have launched measures to halt the epidemic within different 
domains, such as, reduction of exposure to opioids, better treatment to those with opioid 
use disorder, research and development for non-opioid treatment and improved post-
marketing surveillance (Califf, Woodcock, & Ostroff, 2016). This section will address, 
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not exhaustively, binding and non-binding measures dedicated to decrease opioid 
exposure and improve post-marketing surveillance implemented by public authorities. 
Albeit not specific to the opioid crisis, a provision of the Affordable Care Act to ensure 
transparency of gifts and donations for physicians and the FDA guidance for the 
industry with regard to continued medical education will be described.  
4.2.1 The FDA Amendments Act and The SUPPORT Act 
In 2007 the Food and Drug Administration Amendments Act  introduced a new section 
to the FDCA with the Risk Evaluation and Mitigation Strategy Program (REMS) 
(FDCA Title 21 USC §505-1). REMS was created to add measures of safety control for 
specific drugs with risk of serious adverse effects. Under REMS, manufacturers may be 
required to provide a medication guide, or a patient package insert; in some instances, 
providers may have to undergo training to be allowed to prescribe the drug (ibid). In 
2018, the FDA gained authority to order REMS for drugs with risk of abuse under The 
Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment 
(SUPPORT) for Patients and Communities Act (SUPPORT Act 2018). 
  
The SUPPORT Act was passed by Congress to halt the opioid epidemic. The act amends 
the FDCA to strengthen FDA authority. As an example, the SUPPORT Act permits the 
FDA to warrant post-marketing studies by the manufacturers, not only for safety 
purposes but for drug efficacy, something previously required solely prior to drug 
approval (FDCA Title 21 USC §355). This specific amendment applies for opioids, a 
class of drugs commonly approved based on historical studies and for which data for 
efficacy of treatment for chronic pain remains inadequate (Staman, 2018). 
Under the SUPPORT Act, a new section allowing the FDA Secretary to completely halt 
drug distribution in a scenario of high-risk probability of harm to the public was 
included to the FDCA (FDCA Title 21 USC §360). The Secretary may stop distribution 
for a determined period or request for a total recall (ibid).  
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4.2.2 Prescription Drug Monitoring Program 
The prescription drug monitoring program is a state-level intervention that enables 
public officials to follow the amount of controlled substance prescribed and sold 
through an electronic database. It is used by physicians to verify patient’s prior 
prescriptions for controlled substances (Kimberly et al., 2018). Forty-nine of the fifty 
American states have passed legislation to implement prescription drug monitoring 
programs with the intent of reducing abuse, diversion and criminal activity (Davis, 
Johnston, & Pierce, 2015). The number of opioid prescriptions has since reduced 
nationwide, while increased use of illicit heroin and fentanyl has increased (supra 2.1).  
4.2.3 CDC Guideline for Prescribing Opioids for Chronic Pain 
In 2016, the CDC issued a guideline with recommendations on opioid treatment for 
chronic pain. The guideline was created to promote safety and avoid the incidence of 
opioid use disorder (Dowell, Haegerich & Chou, 2016). The authors reveal they reached 
twelve recommendations based on observational studies and low-quality randomized 
clinical trials; in addition, they note that no study of opioid therapy for longer than one 
year was available for the guideline development (ibid). The CDC, henceforth, 
recommends physicians should opt for non-opioid treatment for the management of 
chronic pain; opioids should only be used when benefits outweigh the risk (ibid). A 
management plan between physician and patient with regard to objectives and 
discontinuation when needed must be agreed upon by both parties. Different from what 
the initial label of OxyContin implied, that long-acting formulation protects from 
addiction, the CDC recommends starting treatment with immediate-release (ibid). In 
essence, although the guideline did not contra-indicate opioid therapy for chronic pain 
altogether, it implies opioids should be avoided, and, when unavoidable, cautionary 
steps must be undertaken.  
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4.2.4 The Physician Payments Sunshine Act  
Professional marketing has been shown to alter physician’s treatment choices (Datta & 
Dave, 2016). To manage financial relationships between the industry and healthcare 
professionals state policies have limited or banned gifts to physicians, while several 
academic institutions have prohibited pharmaceutical industry sponsored meals and 
speaker’s fees (Medicare Payment Advisory Committee, 2017).  
As part of the Affordable Care Act, the Physician Payments Act was introduced to 
ensure transparency of physician ownership or investment interests. The legislation 
obliges manufacturers to submit to the HHS, in electronic form, the name, value, date, 
and nature (honoraria, gift, food, travel, education and others), of any payments to 
physicians (Affordable Care Act §6002, 2010). 
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Chapter 5. Medical Opioid Use in Portugal 
The DGS is the central public agency of the Portuguese Ministry of Health and 
possesses administrative autonomy (Regulatory Decree n.14/2012, of January, 25, art.
1). Powers and attributions of the DGS include: to monitor the determinants of health, 
to inform about the health status of the Portuguese population, to plan and implement 
the Health National Plans’ programs and to define public health policies (ibid, art.2 al. 
b),c),d),f)). 
In 2001 the DGS approved the National Plan for the Fight Against Pain. The plan was 
developed with the assistance of the medical association Associação Portuguesa para o 
Estudo da Dor (APED). Its implementation was preceded by research performed by a 
working group in 1999 that revealed 39.1% of the hospitals in Portugal offered services 
specific to pain treatment (Direcção-Geral da Saúde, 2001). The goal was to increase to 
75% the number of dedicated pain services with different levels of complexity: level I, 
an established dedicated service with pain specialist; level II, a service with a 
multidisciplinary team apt to conduct research and teaching of health professionals; and 
level III, a multidisciplinary center for pain treatment affiliated to an academic 
institution (Direcção-Geral da Saúde, 2001).  
In addition to the proposed structural changes, the plan offered general guidance with 
regard to pain evaluation and management. It mentioned opioid use for chronic pain 
unrelated to cancer remained controversial and should be reserved for specific 
situations, those which were not discriminated in the text, under the responsibility of 
experienced clinicians (ibid).  
As part of the effort to raise awareness, the government created the national day for the 
fight against pain, celebrated for the first time on June 14th, 1999. As a result of these 
efforts, services dedicated to the management of chronic pain increased by 40% 
(Direcção-Geral da Saúde, 2008a).  
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The plan was followed by the Program for Pain Control in 2008 and the Strategic 
National Plan for Control and Prevention of Pain in 2013. Following these initiatives 
the management of pain was recognised as a medical specialty by the national 
physician’s council; the Ordem dos Médicos. Strong opioids were included in the list of 
medications subsidised by the State and empirical knowledge regarding the prevalence 
of pain, both chronic and acute, in the Portuguese population, was sought (Direcção-
Geral da Saúde, 2013).  
From 2008 onwards, opioid treatment for chronic pain unrelated to cancer was 
recommended for those with moderate to strong pain refractory to other modalities of 
treatment. In addition, pain as the fifth vital sign was endorsed as a guiding principle of 
the program. 
This chapter describes the structure and normative framework of medical opioid use in 
Portugal. Both binding and non-binding public instruments implementing policies 
aimed at increasing opioid availability will be discussed. The role of Infarmed and 
regulations with regard to drug approval, medical advertisement, labelling, and 
pharmacovigilance will be reviewed and compared to the American counterpart 
discussed in Chapter 4. Finally, data of increased opioids sales and use in Portugal is 
reported. 
5.1 DGS: Guidelines and Regulations for Opioid Therapy 
The DGS is responsible for defining norms and guidance for medical clinical practice 
(Regulatory Decree n.14/2012, of January, 25, art.2 al. a). The legal implications of 
clinical guidance vary within different countries, medical specialties, and the entity 
issuing the recommendations (Coppen, 2005). In some countries, guidelines can be used 
as evidence in a medical malpractice lawsuit, even when not mandatory (ibid). In 
Portugal, the DGS issues clinical recommendations classified as either informative or 
normative, following the former is voluntary, and the latter, mandatory. 
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The DGS stipulates four steps to draft and issue a new regulation. First, a working-
group must elaborate a proposal; second, a public consultation is made available for 30 
days; third, contributions gathered during consultation are revised; and fourth, the 
Scientific Commission of Good Clinical Practices validates the regulation according to 
the level of evidence and recommendation (Direcção-Geral da Saúde, 2019). 
In June 2003, seven years after the launch of the fifth vital sign campaign by the APS, 
and one year after the JC revoked the concept by reinforcing “Pain used to be 
considered the fifth vital sign,” the DGS issued a normative statement that implemented 
pain as a fifth vital sign (Baker, 2017: p.6; Direcção-Geral da Saúde, 2003) (supra 3.1). 
The rule, aimed at health regional administrations and healthcare services, was 
supported by the Commission of the National Plan for the Fight Against Pain and 
APED.  
According to the recommendations described in the statement, pain should be 
systematically documented in a dedicated space on the vital signs sheet with the use of 
validated international scales of pain intensity (Direcção-Geral da Saúde, 2003). All 
alert patients with age equal to or greater than three years old should have their pain 
levels verified  (ibid). The normative document, however, did not define guidelines for 
the clinical management of the identified pain. Opioid therapy was not mentioned in this 
document. 
Despite its obligatory nature, the measurement and documentation of pain as the fifth 
vital sign had not been fully adopted by 2008 (Direcção-Geral da Saúde, 2008a). 
Clinical repercussions of its practice in Portugal have not been studied to date. 
An informative, rather than normative, guideline, with respect to the use of strong 
opioids for chronic pain unrelated to cancer, was dispatched in 2008. The guiding 
principles were addressed to all physicians of the public health system and intended to: 
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“… reduce the prevalence of moderate to strong chronic pain, increase 
adherence of the sick to therapy and improve their quality of life, reduce 
myths and prejudices associated to opioid medications and prevent its illicit 
use” (Direcção-Geral da Saúde, 2008b: p.1) .  2
The guideline clarifies the use of opioid for chronic pain unrelated to cancer has 
increased in parallel to results of clinical studies and systematic reviews of which the 
document makes reference to two studies: a systematic review and a meta-analysis. The 
systematic review concludes the short-term efficacy of opioids was good when 
compared to placebo but not to other modalities of pain treatment (Kalso et al., 2004). 
The same review states the short-term follow-up precludes any conclusion with regard 
to safety, specifically tolerance and addiction (ibid).  The meta-analysis included 41 
randomized trials with average duration of treatment of 5 weeks (Furlan et al., 2006). 
All opioids were superior to placebo but only strong opioids were superior to other 
types of analgesia (ibid). Only 3 of the 41 trials contemplated following the patients for 
signs of addiction, therefore a significant conclusion with regard to long-term adverse 
effects was not possible. (ibid).  
Despite the lack of evidence the guideline embraces the idea that concerns for tolerance 
and addiction are unfounded and notes that the World Health Organization pain scale 
indicated for patients with cancer is increasingly being applied to patients without 
cancer (Direcção-Geral da Saúde, 2008b).  
In a less permissive tone, the guiding principles invoke some restrictions: strong opioids 
should be considered a therapy of last resort, indicated to patients with moderate to 
severe chronic pain when refractory to other modalities of treatment (ibid). The patient 
must consent to treatment after fully informed of the risks and agree to comply to the 
rules, such as, take the medication as prescribed, not request medication from a different 
physician, and communicate immediately to the police if the medication is stolen (ibid). 
 This citation was originally in Portuguese and was translated to English by the author2
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Less than a year before the President of the United States declared the opioid crisis a 
public health emergency, another step was taken in Portugal to advance the treatment of 
chronic pain with opioids. An ordinance was passed in order to increase the subsidy for 
strong opioids. Up to this point the government co-payed for 37% of the drug’s cost, 
under the new regulation opioids for moderate to strong pain, when prescribed in the 
setting of specialized pain or palliative services, receives 90% coverage of the costs by 
the State (Ordinance n. 329/2016, of December, 20, art.1 and n.1 of art. 3). The list of 
drugs contemplated in this ordinance includes the opioids previously made available by 
the state, buprenorphine, fentanyl, and morphine, in addition to new therapeutic options: 
hydromorphone, tapentadol, oxycodone and oxycodone with naloxone (ibid, annex).  
Following the American footsteps, Portugal has embraced the fight against pain and the 
American narrative constructed in order to justify the liberal use of opioids. It is 
noteworthy that the Portuguese clinical guideline for opioid use in chronic pain is more 
cautious than the American recommendations supported in 1996 and bears more 
similarities to the CDC guideline published in 2016 (supra 4.2.3). Nonetheless, a 
normative structure that allows for easier access to opioids for the treatment of chronic 
pain has been placed despite the paucity of evidence for its safety.  
5.2 The Infarmed 
The government institution analog to the FDA in Portugal is the Infarmed: a public 
agency responsible for the management and control of drugs and medical devices with 
national jurisdiction (Decree-Law n.º 46/2012, of February, 24, n.1 of art.2). Infarmed is 
a public institution under the supervision of the Portuguese Ministry of Health that 
disposes of financial and administrative autonomy (ibid n.1 e 2 of art.1) The institute is 
also an authority in several domains of activities related to health. It contributes to the 
development and implementation of health policies, supervises production, distribution, 
and advertisement of health products, monitors drug consumption, promotes research 
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activities, verifies that compliance to health codes, regulations, and laws are being 
respected, among others (ibid n.1 e 2 of art.3).  
As is the case with the FDA, Infarmed is responsible for drug licensing, supervision of 
the advertisement’s contents, labelling, and pharmacovigilance (Decree-Law n.º 
176/2006, August, 30 n.2 of art.166). With the purpose of delineating the normative 
similarities and differences with its American counterpart a general, but not exhaustive, 
review of Infarmed’s legal framework on these topics will be addressed in this chapter. 
5.2.1  Medical Advertising and Labelling 
When compared to American marketing regulations, Portuguese rules are notably more 
stringent. As is the case with opioids, drugs that require prescription, belong to the 
psychotropic class of medications, or participate in the National Health Service subsidy 
program are prohibited to be advertised to the general public. (ibid n.º 2 of art. 152º 
alíneas a), b), e c)). On the contrary, over-the-counter drugs may be advertised by 
television, internet, radio and others, however misleading information, and comparative 
advertisements to the public are unlawful and subject to sanctions (ibid n.º 1 of art. 
153º).  
Free sample distribution to patients is forbidden (ibid n.º 6 of art.153º). In contrast with 
the United States free sample distribution to physicians is only allowed at the lowest 
dosage and with a box label displaying a free sample warning (Decreto-Lei n. 128/2013 
of September, 5 al. c) and d) of art.162º) (5.1.1 supra). 
Marketing of medications that require prescription is allowed to healthcare professionals 
(Decree-Law n.º 176/2006 of August, 30 art. 154º). Advertising campaigns to 
physicians do not require pre-approval by the Infarmed, however, the manufacturer is 
obliged to deliver a copy of the advertising material to the Infarmed within ten days of 
the publishing date (Decree-Law n.º 5/2017 of January, 6 art. 11º ). The content of the 
advertisement may not be misleading; if a breach is identified Infarmed may open 
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inquiries to verify the possible offence (Decree-Law n.º 176/2006 of August, 30 n.º 3 of 
art. 150º and al. c) of art. 164º). 
Sales representatives may visit physicians employed by the National Health Service so 
long they are registered with Infarmed (Despatch n.º 8213-B/2013 of June 24, n. 1º of 
art. 2º  and n.1º  of art 3º). Sales representatives’ visits are limited to six per year for 
each institution and to a maximum of eight physicians per day (ibid n. 1º e 4º  of art. 4º). 
This regulation contrasts with the unregulated American counterpart (supra 5.1.1) 
Physicians may be subsidised to attend scientific meetings as long as the sponsorship 
does not influence medical practice and dispensing of the pharmaceutical product 
(Decree-Law n.º 176/2006 n.º 4 of art. 158º). Benefits in kind to physicians are not 
permitted, except when due to professional activity, such as, continued medical 
education, scientific communications, and drug marketing, as long as the payment does 
not oblige the physician to prescribe the drug (ibid n.º 1, 2 and 4 of art. 158º). The 
manufacturer is obliged to report the payment to Infarmed within 30 days (Decree-Law 
n.º 5/2017 of January, 6 art. n.º 10). 
Private donations to the National Health Service must be approved by pharmaceutical 
companies and other companies related to health technology that may influence 
exemption and impartiality are not allowed (Decree-Law n.º 5/2017 of January, 6 n.º 1 
of art. 9º). Pharmaceutical companies are not allowed to sponsor medical education 
events (ibid n.º 3 of art. 9º). 
The manufacturer is criminally responsible for the complete and accurate information 
provided in the drug’s label. (Decree-Law n.º 176/2006 of August, 30 art. 110º). 
5.2.2 Drug Approval 
The Medicine Act, enacted on August 30, 2006, is a decree-law dedicated to the 
regulation of production, quality control, safety, efficacy, commercial distribution and 
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pharmacovigilance of drugs in Portugal (ibid n.º 1 of art. 1º). The act unifies previous 
established norms and absorbs the European Union’s legislations with regard to 
medication use, distribution and advertisement (ibid n.º 3 of art.2º alínea d), art. 54º).  
There are different avenues through which Infarmed may grant drug approval for 
distribution. The procedure may be a centralised process performed by the European 
Medicine Agency, usual for new drug applications, or simplified (Botelho, 2019). The 
latter offers two possibilities: mutual recognition procedure when approved by another 
member state or as Portugal as the reference State and a decentralised procedure when 
the application is dispatched to different member states simultaneously (Decree-Law n. 
176/2006 of August, 30 nº 1 e 2 of art.19º and al. a) of art. 40º ). 
As in the United States, clinical trials data are required for new drug approval, but if 
efficacy and safety have been observed within the European Union for at least 10 years, 
study results are exempted (ibid art. 20º). The number of clinical trials required to 
approve a new drug is not specified (ibid nº 2 al. j) do art.15º). New therapeutic 
indications for previously approved drugs require the submission of new clinical trials 
to that end (ibid Art. 21º). 
Once approved, medications that require medical prescription, as opposed to over-the-
counter medications which do not require prescription, are only sold by pharmacies 
registered with Infarmed (ibid art. 79º). Over-the-counter medications are commonly 
used to treat mild medical conditions with a long established safety profile, while 
prescribed medications demand closer medical monitoring. Importantly, opioids do 
require a medical prescription, however, different from the United States any physician 
is allowed to prescribe opioids in Portugal, no special prescription pad or identification 
is needed (supra 4.1.2). Portugal issues both paper and electronic prescription. The 
electronic system, launched in 2012, maintains the complete prescription history of 
every patient, therefore, similar to the American Prescription Monitoring Program, 
physicians can check which medications were previously used. 
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Lastly, it is the Infarmed’s responsibility to supervise and audit all pharmacies (Decree-
Law n.º128/2013 of September, 5 n.º 1 of art. 176º) (supra 4.1.2), different from the 
United States that disposes of the DEA to survey irregular activities of controlled 
substances . 
5.2.3 Pharmacovigilance 
When the Portuguese National Pharmacovigilance System was implemented during the 
nineties only life-threatening adverse events were communicated by healthcare 
professionals and pharmaceutical industries (Decree-Law n.º 176/2006 of August 30 art. 
169º; Herdeiro et al., 2012). From 2007 onwards, pharmacies were normatively bound 
to join the surveillance collaboration (Decree-Law n.º 307/2007 August, 31 art. 7º). 
Concurrently, an internal pharmacovigilance system became an obligatory requirement 
for pharmaceutical industries applying for new drug approval (Decree-Law n.º128/2013 
of September, 5 n.º 1 of art. 170º). As in the United States, the information gathered by 
the industry must be systematically shared with public agencies, both Infarmed and the 
European Commission; (Decree-Law n.º128/2013 of September, 5 n.º 1 al. b) and g) of 
art. 171º) (supra 5.1.4).  
In 2010, European legislation broadened the definition of adverse events to include any 
unwanted reaction, such as therapeutic mismanagement, off-label use, and misuse; as a 
result, consumers gained access to the spontaneous notification system offered by 
Infarmed (Decree-Law n.º128/2013 of September, 5 n.º 1 of art. 171º). Portugal and the 
European Union are committed to communicate and share the results of their 
surveillance activities (Decree-Law n.º128/2013 of September, 5 n.º 1 of art. 174º). 
Pharmacovigilance practices have evolved and broadened over the years. However, as is 
the case in the United States, it is the manufacturers’ responsibility to carry post-
marketing clinical studies upon request or voluntarily, the party less interested in 
detecting serious adverse events (Decree-Law n.º128/2013 of September, 5 n.º 1 of art. 
175º) (supra 4.1.4).  
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5.3 Chronic Pain and Opioid Consumption in Portugal 
Portugal is home to an average population of 10 million people (PORDATA, 2019). A 
cross-sectional study performed between January 2007 and march 2008, estimated the 
prevalence of chronic pain with moderate to severe disability, defined by difficulties 
with home responsibilities, recreational activity, social activities and work, to be 
approximately 11% (Azevedo et al., 2013a). Based on the same cohort, Azevedo et al. 
(2016), estimated the economic impact of chronic pain costs Portugal 2.7% of the 
national gross domestic product and of this measure more than 50% are secondary to 
indirect costs: lost work days, early retirement, and unemployment. Approximately 4% 
of patients with chronic pain used opioids (Azevedo et al., 2013b). 
According to data provided by Infarmed to the author, medical opioid consumption has 
increased approximately by 54-fold measured by the number of packages dispensed 
between 2000-2018; 22,922 packages dispensed in 2000 compared to 1,243,894 in 2018 
(Figure 13). This measurement pertains to opioids dispensed in the outpatient setting 
including the following opioids: fentanyl, morphine, oxycodone, buprenorphine, 
hydromorphone, combination of oxycodone with naloxone and tapentadol. Oxycodone 
sales began in 2016 and increased by 130% between 2017 and 2018; from 3,577 to 
9,650 packages (Figure 14). With the exception of morphine, the consumption of all 
types of opioids are trending upwards; most remarkably fentanyl, buprenorphine and 
tapentadol (Figure 14). 
Tapentadol and buprenorphine have not been previously addressed in the dissertation. 
Buprenorphine is a partial opioid agonist, used for pain treatment as well as for opioid 
use disorder management, its consumption increased from 3,780 packages in 2000 to 
352,011 in 2018 (Figure 14). Tapentadol was approved by the European Medicine 
Agency in 2010. As tramadol, it has dual action; it inhibits norepinephrine uptake and 
acts on opioid-mu receptors (Mosele, Almeida, & Hess, 2018). Reportedly, it has less 
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gastrointestinal side effects and develops less tolerance (Mosele, Almeida, & Hess, 
2018). In six years, its use has increased from 21 packages in  2012 to 936,238 in 2018 
(Figure 14).  
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Figure 13: Total opioid consumption: Health National Service/Portugal, 
2008-2018.
Source: CCMSNS (Centro de Controlo e Monitorização do SNS) 
Center of Control and Monitoring of the National Health System 
In the period between January 1, 2000 and December 31, 2013, the 
data refer to medicines reimbursed and dispensed on an outpatient basis 
to users of the National Health Service in Mainland Portugal. In the 
period between January 1, 2014 and December 31, 2018, the data refer 
to medicines reimbursed and dispensed on an outpatient basis to users 
of the National Health Service and public subsystems, in Mainland 
Portugal. This database does not include medicines related to the 
hospital environment (translated to English by the author). 
Methadone consumption is not included. 
Graph produced by the author with data provided by Infarmed 
(supra Methods). 
Methadone consumption is not included
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Source: CCMSNS (Centro de Controlo e Monitorização do SNS) Center of Control 
and Monitoring of the National Health System 
In the period between January 1, 2000 and December 31, 2013, the data refer to 
medicines reimbursed and dispensed on an outpatient basis to users of the National 
Health Service in Mainland Portugal. In the period between January 1, 2014 and 
December 31, 2018, the data refer to medicines reimbursed and dispensed on an 
outpatient basis to users of the National Health Service and public subsystems, in 
Mainland Portugal. This database does not include medicines related to the 
hospital environment (translated to English by the author). 
Methadone consumption is not included. 
Graph produced by the author with data provided by Infarmed (supra 
Methods).
Figure 14: Opioid consumption, by type: Portugal, 2000-2018.
This data does not discriminate between different pain etiologies. Therefore, it is not 
possible to conclude whether pain management for cancer patients, pain management 
for acute and chronic pain unrelated to cancer, or all of them have expanded. 
According to the EMCDDA (2019), drug-induced mortality rate among adults aged 
15-64 years increased between 2011-2015 in Portugal and is currently in decline at 
approximately 4 deaths per million; three in every four were attributed to opioids 
although combinations with other drugs were frequent (Figure 15). Five in every one 
thousand individuals were deemed high-risk for opioid use in 2015; the European 
average ranges between 0,5 and 8 (EMCDDA, 2019). The total number of patients 
requiring opioid substitution treatment declined from 24,312 in 2007 to 16,888 in 2017 
(EMCDDA, 2019). Opioids are responsible for 40% of admissions to specialised drug 
treatment, a reduction compared to over 60% in 2008 (EMCDDA, 2019). Heroin users 
seeking treatment decreased from 3000 to approximately 1000 between 2009-2012 and 
has maintained this level since (EMCDDA, 2019).  
Importantly, an increase in opioid use disorder and drug-induced mortality have not 
been observed in parallel to the increase in medical opioid use, however, 2018 and 2019 
indicators are not yet available.  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Figure 15: Overdose deaths: Portugal, 2006-2016. (EMCDDA, 2019)
PART II 
Chapter 6. Opioid Use in Portugal: Perceptions of Portuguese Key-Informants 
The author was particularly interested in exploring key informant’s views and 
perceptions of medical opioid use in Portugal considering the adequacy of the normative 




The author conducted a qualitative study with semi-structured interviews. Health 
professionals involved with pain management and members of medical societies or 
active in national public health governance were considered potential key-informants. 
Key-informants were recruited via email to public agencies, medical associations, and 
non-governmental organisations, namely: Intervention Unit in Addictive Behaviors and 
Dependencies/Serviço de Intervenção nos Comportamentos Aditivos e na 
Dependências, Infarmed, DGS, Portuguese Association for the Study of Pain/
Associação Portuguesa para o Estudo da Dor, Portuguese Institute of Oncology/
Instituto Português de Oncologia, Order of Portuguese Physicians/Ordem dos Médicos 
de Portugal , Portuguese Society of Anesthesiology/Sociedade Portuguesa de 
Anestesiologia, Order of Portuguese Nurses/Ordem dos Enfermeiros em Portugal, 
Portuguese Association for Addiction/Associação Portuguesa de Adictologia, and 
Narcotics Anonymous/Narcóticos Anónimos. The invitation explained the nature of the 
study and asked for indications of pertinent key-informants with respect to opioid use in 
Portugal. Following the snowball sampling technique, interviewed key-informants were 




6.1.2 Data Collection 
A semi-structured guideline composed of eight questions was developed by the author 
(Appendix A). The interviewees were asked about their perceptions concerning the 
opioid use in Portugal, adequacy of the Portuguese regulatory framework and use of this 
class of medication to treat chronic pain unrelated to cancer. Participants read and 
signed the informed consent form prior to the interview (Appendix B). Interviews were 
anonymised and kept confidential. Interviews were conducted in Portuguese, face-to-
face, and in both the cities of Lisbon and Porto. Data collection depended on 
institutional response, as well as on suggestions from interviewed key-informants, 
therefore, theoretical saturation of the data was not sought. Interviews were conducted 
during the months of October and November 2019.  
6.1.3 Data Analysis 
Interviews were recorded and transcribed verbatim by the author. Data analysis of the 
transcripts was performed using thematic analysis, a method of qualitative descriptive 
research. Thematic analysis is considered a basic tool of qualitative analysis adaptable 
to different theoretical frameworks, therefore unbound to a specific theory (Braun & 
Clarke, 2006). The process is flexible and iterative being constantly revised upon new 
observations (ibid). Its main purpose is to detect common themes among the gathered 
data pertaining to respondents views, underlying ideas, assumptions and description of 
phenomena (ibid).  
Manually, the author reviewed the data and created codes to form themes that 
represented the main ideas and topics discussed by the key-informants. The 
identification of themes followed the process proposed by Vaismoradi, et al., (2016) 
which divides the process in four phases: initialization, construction, rectification and 
finalization. These phases consist of reading and rereading transcripts while taking 
notes, labelling and comparing, connecting themes to previous knowledge and 
developing a narrative (Vaismoradi, et al. 2016).   
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Themes were analysed at a semantic level rather than interpretative level: the goal was 
to address, concretely, key-informants views on the subject as opposed to reveal the 
origins of the underlying perceptions. Participants’ direct citations were translated to 
English by the author 
Results may be interpreted through both deductive and inductive reasoning. While, a 
deductive process introduces an idea and explores the data with the intent of responding 
to a predefined hypothesis, inductive bears no obligation to answer any previous 
question or fit into a specific framework; with inductive analysis the researcher is 
longing for new perspectives (Braun & Clarke, 2006).  
This dissertation begins with the assumption that health law may have played a role in 
the emergence of the opioid epidemic and that an overview of the Portuguese normative 
structure of medical opioid use may reveal strengths and weaknesses in face of this 
threat. The author, for this reason, used a mixed approach for data analysis, at times 
deducing upon observations documented in the description of Part I, and other times 
expecting new perspectives to emerge from the key-informants. 
6.2 Results 
In total, the author interviewed five key-informants: four physicians and one nurse. 
Snowballing sampling resulted in two of the five interviews. Interview duration ranged 
between twenty and forty minutes. Five themes were identified: limited efficacy of 
opioid therapy, underutilisation of opioids in Portugal, preventive measures for opioid 
overuse, physician relationship with the pharmaceutical industry and specific traits of 
the United States. Each theme is described below in detail.  
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6.2.1 Limited efficacy of opioid therapy 
The limitations of opioid therapy to treat chronic pain was consensual among 
respondents. The views shared described an important role for opioids in pain 
management but not in every circumstance or every patient. Participants disclosed the 
following observations: 
There is a group of patients that benefit {from opioids}, however, not all of 
them, and this seems to me the point in case and the future of the role of 
opioids to treat chronic pain, knowing how to identify patients… 
… {opioids} however should not be viewed as a panacea, meaning it is 
useful for every patient and any type of pain, because that is not true. 
Opioids should not be viewed as first-line treatment for chronic pain 
unrelated to cancer, however when other strategies fail, opioids frequently 
or in many occasions have an important role. 
However, we should not exaggerate and say that opioids are not useful, that 
opioids are poisonous, and it is something that we should avoid. I think 
somewhere in the middle is the balance, either always or never. 
Despite the acceptance that even if limited there is some role for opioids for the 
treatment of chronic pain there is concern for the lack of robust data to defend this 
practice.  
There was a transposition of the principles we use for treatment of 
oncological to non-oncological chronic pain, almost immediately, without 
large studies to defend that with large robust results. 
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An understanding that pain management has several different tools and should be 
addressed by a multidisciplinary team places opioids as part of a broader 
armamentarium for pain control.  
There must be a multimodal approach and our unit has pharmacologic 
treatment, of course, with opioids, acupuncture, some invasive techniques 
with {nerve} blocks and infiltrations, we value very much functional 
rehabilitation, and that is why we have a physiatrist.  
Opioid’s limitations and its potential side effects should influence patient education 
regarding efficacy and side effects. The following citations reflect these concerns:  
There was an increase in the use of opioids for the treatment of pain and 
chronic pain, but it is necessary to effectively ponder its efficacy to people. 
I think it is the education, education takes time, explaining a disease takes 
time, but this is what we will face, and in fact, be very honest with ourselves, 
with the staff and with the patients, tell them what we are doing and the 
importance of what we are doing. 
Because we are authorising a medication not exempt of risks, and that after 
some time does not benefit patients, it does not make sense to keep it 
indiscriminately only due to the assumption that if stopped the situation will 
worsen.  
 6.2.2 Underutilization of opioids in Portugal 
In the past, opioid therapy was restricted to treat severe pain in patients with cancer, it 
was the participants’ opinion that opioids were essentially under prescribed. As one 
participant said: 
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Ten years ago, I could count on my fingers how many patients would show 
up taking strong opioids, many show up now.  
Different reasons for the scarce use of opioids were proposed by the participants, among 
them the heroin epidemic that afflicted Portugal in the nineties and the lack of medical 
education in pain management. These perceptions are indicated in the following lines:  
In Portugal we were always very careful with drugs containing opioids, 
there was a serious heroin epidemic that prompted opioid demand including 
cough syrup with codeine, gradually these medications were removed from 
the market, therefore, the physicians never prescribed them a lot except in 
the situation of cancer.  
In Portugal, fortunately, to a certain point, people are afraid of opioids, the 
physician himself, and therefore, {they} don’t use it, rather they prefer to 
ignore it than to test it, that has been the rule in Portugal. 
According to one participant, the opioid underutilisation justifies the recent increase in 
opioid prescriptions:  
More opioids are prescribed now than 10 or 15 years ago, this is not, however, 
necessarily alarming, because we may be facing a difference between not 
treating pain entirely or treating something, I think this distinction is 
important, from zero to ten it is not necessarily an abuse, is it? 
For others, public campaigns for medical awareness and pharmaceutical medical 
marketing were considered important factors for the increase in opioid dispensing by 
physicians of various medical specialties. Views regarding changes in medical practice 
are demonstrated in the following extracts:  
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A lot of medical education and divulgation around the theme of pain occurred 
in the past 15 year, and I think that has contributed decisively to this shift, also, 
coming from the pharmaceutical industry, there has been a more active 
marketing.  
We have greater awareness of the professionals for the treatment of pain, for 
the identification of pain but also I think there is a stronger influence of the 
marketing from the pharmaceutical industry.   
An increase in opioid prescription, in urgency units, as well as from physicians 
of other specialties, orthopedic, general medicine, family medicine, increased 
exponentially. 
 6.2.3 Preventive measures for opioid overuse 
Participants alerted that aberrant opioid prescriptions are beginning to surface and that 
preventive measures to avoid inadequate opioid use are needed. Concerns for physician 
mismanagement of the use of opioids were cited as following: 
In our units, patients arrive with opioid prescriptions, sometimes in high doses, 
with no indication for opioids, much less for those dosages. 
When clinicians do not know them {opioids} well, when they do not master 
their indications, their contraindications, their complications, this opens the 
door to bad practice. 
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At times, an opioid is not the most indicated, not for the patient profile, or the 
clinical context, and following that, the patient did not have supervision or 
clinical follow-up. 
Different preventative measures were recommended by the participants. Among them, 
improved medical education in pain management, systematic monitoring of opioid use 
and distribution and careful patient evaluation and follow-up are described below.  
It is important that all professionals are educated to treat pain, but also to refer 
patients in refractory situations. 
A broad training is needed, namely at the level of younger doctors who have 
not gone through those phases {of the Portuguese heroin epidemic}. 
I would like to see monitoring, who is prescribing? What type of patients? 
Which types of strong opioids? I would like to know that. 
Hardly a patient {with chronic pain} will take 20 minutes in his first visit, the 
average time will be one hour or more in this first encounter. 
The patient profile is very important, previous psychological ailments are taken 
into consideration, it is always valuable to verify if the patient has the profile in 
terms of adherence to safety and the context the patient lives in. 
Consensually, participants agreed the public program of electronic prescription is an 
important tool to aid with monitoring of opioid consumption for the prevention of 
opioid misuse. 
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It is an effective safety measure that allows us to precociously identify 
situations of bad use or abuse of opioids. 
Through electronic prescription, Infarmed may track the medication from the 
moment it is prescribed by the physician to the moment it is filled to the patient.  
 6.2.4 Physician relationship with the pharmaceutical industry 
Participants shared a positive perception of the pharmaceutical industry as a provider of 
access to continued medical education. Their appreciation can be verified in the 
following excerpts: 
I believe the pharmaceutical industry has a very important role in medical 
education, because it is with the help of the pharmaceutical industry that we 
obtain some quality education, look, I am here at this conference for which my 
department will not pay the registration, if it wasn’t for the pharmaceutical 
industry I would not be able to attend. 
Nowadays, more and more, depending on the socioeconomic conditions of 
health professionals in question, if there is no support from the pharmaceutical 
industries, health professionals in Portugal are isolated from the world. 
The opinion that the pharmaceutical industry is a positive asset was corroborated by the 
wide acceptance of the legislation concerning the relationship between physicians and 
the pharmaceutical industry. Most participants deemed protective the need for full 
disclosure regarding industry gifts or donations and possible conflicts of interest for a 
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healthy relationship between physician and industry. Commendation for the Portuguese 
legislation regarding by participants are shown by these quotes: 
These situations are very well regulated by the Infarmed, in terms of support I 
have to prove to my department that I will attend the conference and I have to 
declare who is sponsoring it, if myself or a laboratory, and how much is being 
spent. 
Legislation controls without limiting access, I honestly don’t see the necessity 
of changing the existing legislation in Portugal in its substance, what we have 
now is adequate. 
Everything is transparent, I have to sign contracts and declare my conflicts of 
interest, everything is notified on Infarmed. 
 6.2.5 Specific traits of the United States 
The risk of having a similar opioid epidemic in Portugal was not entirely rejected by the 
participants, however, they argued differences between countries with respect to 
medical malpractice lawsuits and marketing legislation were highlighted as protective 
and suggestive that such an occurrence is unlikely.  
Participants remarked access to treatment for pain is a human right. Still, while due 
diligence to the respect of this right may be taken to the court of law in the United States 
this practice is not common in Portugal. This perception is observed in the following 
passage: 
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They {Americans} are very aggressive in the way they sue physicians, namely, 
if you don’t treat my pain well, I will sue you, this does not happen in Europe.  
In agreement with this dissertation’s premise, which emphasis the role of health law in 
public health, the absence of direct-to-consumer marketing was considered an important 
difference between American and European legislation, as observed in the following 
excerpt:  
There are many different things in the United States when compared to Europe, 
pharmaceutical industries may market medications directly to patients, in 
Portugal and Europe this does not happen, and I think that is very good, I 




The author’s findings was that although key-informants acknowledge the limitations of 
opioid use for the treatment of chronic pain unrelated to cancer they share the opinion 
that there is clinical indication for a subset of patients, despite scant empirical evidence 
to support it.  
Several studies carried out to address the effectiveness of opioids in patients suffering 
from chronic pain, lasted for only 5 weeks to 3 months and did not attest for the 
sustained response to treatment in the long term. (Furlan et al., 2006; Martell et al., 
2007, Chou et al., 2009; Papaleontiou et al., 2010; Chou et al., 2015; Busse et al., 
2018). In 2018, Busse et al. reviewed 96 randomised control trials involving 26,169 
patients, of those, 42 studies followed patients for longer than 3 months. When opioids 
were compared to placebo a slight superiority was reported for opioid treatment, 
however, the level did not reach the threshold for minimally important difference, a 
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measurement created to quantify the least amount of improvement deemed meaningful 
by the patient (Busse et al., 2018). The lack of pain relief in the long-term was 
confirmed by Veiga et al., (2019) in a two-year multicenter prospective cohort study 
completed in Portugal. Furthermore, safety data on opioid use disorder in the long-term 
is scarce, due to the short duration of the trials and variations within definitions and 
methods to identify opioid use disorder (Chou et al., 2015). 
Participants’ impressions on the increase of opioid use are consistent with the data 
depicted in this dissertation (supra 5.3). Opioid underuse was attributed to Portugal’s 
past difficulties with heroin addiction, but also to physician’s fear of using opioids. At 
this point, one could argue fear was due cautiousness and that the jargon ‘opiophobia’ 
was the result of marketing strategies employed in the United States and disseminated 
by medical guidelines based on expert consensus alone (supra 3.1). Similarly, the 
possible transition to opioids overuse was deemed, by participants, to be secondary to 
public awareness campaigns and increased advertisement. The role of American 
marketing and medical knowledge production is verified by the adherence to the 
concepts of pain as a fifth vital sign and the opioid use for chronic pain unrelated to 
cancer both of which have been embraced by Portuguese and other European countries’ 
medical practice and legislation (Levy, Sturgess & Mills, 2018).  
As noted by respondents, signs of excessive and unwarranted opioid prescriptions are 
beginning to show. To counteract opioids overuse, participants suggested specialised 
pain management education and closer monitoring of opioids prescription, dispensing 
and sales, and careful patient evaluation. The national electronic prescription program 
was identified as a preventive measure to opioid mismanagement. With this system, like 
the American prescription drug monitoring programs, prescriptions signed electronically 
are accessible to any physician, and, therefore, overprescribing is avoided (supra 4.2.2). 
In the United States, prescription drug monitoring programs have shown to reduce 
opioid prescribing rates and overlapping prescription indicating the program prevents, 
to some extent, opioid misuse (Strickler et al., 2020; Strickler et al., 2019).   
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Physician advertising and ties with the industry were, in the contrary, not deemed 
inappropriate by participants, in fact, most considered essential the pharmaceutical 
sponsorship for continued medical education. Participants argued that industrial ties are 
acceptable once notification of gifts and donations are obligatory through the Infarmed’s 
electronic system, as in the United States with the Physician Payments Sunshine Act 
enacted in 2010 (supra 4.2.4). In the United States, empirical evidence has shown 
association between gifts and brand prescriptions and reduced industry transfers to 
physicians once obligatory public reporting was implemented (Brunt, 2019). 
Two participants viewed excessive medical litigation in America as a possible culprit to 
the opioid epidemic. Taking into consideration that access to pain treatment is a human 
right, their idea was that the legal duty to relieve pain may have pushed physicians to be 
overzealous. Families who have sued physicians in the United States for negligence of 
pain treatment have managed to recover meaningful damages by jury’s verdicts (Rich, 
2001). Historically, it has been the fear of legal sanction when prescribing opioids that 
has guided medical practice (Dineen & DuBois, 2016) (supra 3.1.2). It is not clear if 
fear of litigation for undertreating pain had a significant role in the epidemic.  
6.4 Study Limitations 
The research question of this study is original and although the author interviewed few 
participants the aim of this study was not to achieve theoretical saturation but rather to 
interview pertinent healthcare professionals specialised in the field of pain management 
in Portugal. Participants were reached through direct contact of public institutions and 
medical associations as well as by personal suggestions of participants themselves, 
therefore, promoting a robust ecological validity. Nonetheless, the study’s external 
validity would have been stronger if greater participation from the contacted institutions 
was achieved (Nowell, 2017). 
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Despite good data collection, face-to face, which strengthens credibility, results were 
not shared with participants after the interview and the data were interpreted solely by 
the author, hence, internal validity is weak (Nowell, 2017). A robust amount of 
transcribed data was cited in order to circumvent this limitation. 
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Chapter 7. Dissertation´s Final Conclusions  
It is undeniable that the American opioid crisis was triggered by the pharmaceutical 
industry and perpetuated by opportunistic individuals, including physicians and private 
companies willing to commit fraud (supra 3.2). However, it is also patent that 
permissive health laws allowed for these practices to be set in motion. Legislative 
counter-measures such as the SUPPORT Act and the Physical Payments Sunshine Act, 
which, among others, added measures of safety to opioid patient package insert and 
strengthened the control of gift and donation from the pharmaceutical industry to 
physicians, respectively, are evidence that health laws improvements were required to 
prevent further injudicious actions (supra 4.2.1 and 4.2.4). 
The SUPPORT act empowered the FDA to demand post-marketing studies, henceforth, 
rendering the process of drug approval more safe, especially with drugs approved based 
on historical studies, such as opioids. The act also allows for a complete stop of drug 
distribution when deemed appropriate by the FDA secretary, enabling a prompt response 
rather than a delayed one and granting relevance to data gathered by pharmacovigilance 
activities. 
Drug approval and pharmacovigilance procedures are very similar among the two 
countries, however, different from the United States, Portugal does not allow direct-to-
consumer medical advertisement of drugs that require prescription, and advertising to 
physicians is strictly controlled; the number of sale representative’s visits to physicians 
is limited and, gift and donations are kept to a minimum (supra 5.2). Furthermore, 
legislative counter-measures implemented in the United States to halt the epidemic, 
namely, strict transparency of industry ties to physicians and prescription control 
through an electronic system, are already part of the Portuguese health laws framework. 
Besides intensive marketing strategies, pharmaceutical companies, most evidently 
Purdue Pharma, succeeded in modifying non-binding rules present in medical 
guidelines. Pain management guidelines were systematically altered in the United States 
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with the approval of medical associations and pain management experts to impart the 
idea that opioid was safe for chronic pain unrelated to cancer. This premise was 
distributed world wide promoting guideline changes and creating an unsafe perception 
of the risks of opioid treatment. 
It is noteworthy that changes in behaviour of medical practice with regard to broadened 
indications for opioid use, despite limited data to support it, have crossed the Atlantic 
and along the years seeped into Portugal’s national guidelines. In specific, normative 
changes such as the adoption of pain as the fifth vital sign and opioid use for chronic 
pain unrelated to cancer were approved (supra 5.1). This is particularly concerning 
when opioids can be freely prescribed by any physician, with no specific prescription or 
training required, in the setting or rising opioid sales (supra 5.3).  
Portuguese pain specialists who participated in this study argue that national legislation 
ruling opioids’ prescriptions, sales and marketing is adequate to maintain appropriate 
access to pain treatment while avoiding medical overprescription (supra 6.2.4). 
Nonetheless, they suggest that measures to prevent opioid mismanagement are required, 
among them, specialized education in pain management for healthcare professionals, 
patient education about opioids risks and benefits, and systematic surveillance of 
opioids’ sales (supra 6.2.3). 
In conclusion, there is indication that lenient laws with relation to drug approval, sales, 
marketing, and labelling have partly contributed to the American epidemic. While 
relevant health laws enacted in the United States to halt the epidemic are in force in 
Portugal, implementation of preventive measures for opioid mismanagement by 
physicians are recommended.  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Appendix A: Semi-Structured Interview Guiding Questions

1. Have you observed changes in the use of opioid drugs in the last decade in Portugal 
2. What is your opinion on the use of opioids for the treatment of chronic pain not 
related to cancer? 
3. What are the positive and negative aspects of the normative order that govern the 
control of the class of opioid drugs in Portugal? 
4. What is your impression of the concept of pain as the “fifth vital sign”? 
5. What is your opinion on the laws that regulate the role of the pharmaceutical industry 
on medical practice in Portugal? 
6. Would you recommend changes to the Portuguese regulatory framework on these 
topics? 
7. In your opinion, is it possible for the American epidemic to reproduce in Portugal? 
Why? 
1. Observou mudanças no uso de medicamentos opióides nesta última década em 
Portugal 
2. Qual é a sua opinião sobre o uso de opióides para o tratamento da dor crônica não 
relacionada ao cancro? 
3. Quais são os aspetos positivos e negativos da ordem normativa que regem o 
controlo da classe de medicamentos opióides em Portugal? 
4. Qual a sua impressão sobre o conceito de dor como o “quinto sinal vital”? 
5. Qual a sua opinião sobre as leis que regulam o papel da indústria farmacêutica 
sobre a prática médica em Portugal?  
6. Recomendaria mudanças para o quadro normativo português nestes temas? 
7. Na sua opinião, é possível que a epidemia americana se reproduza em Portugal? 
Porquê? 
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Appendix B: Informed Consent 
Researcher: Anna Maria Delios 
Advisor: Prof. Paula Lobato de Faria, PhD 
Organization Name: National School of Public Health / Universidade Nova de Lisboa 
(ENSP / UNL) 
Project Name: The American Opioid Epidemic from a Normative Perspective: Lessons 
for Portugal 
Study information 
Within the scope of the master's degree in Public Health at ENSP / UNL and under the 
guidance of Dr. Paula Lobato de Faria, PhD, professor at ENSP / UNL, I invite you to 
participate in a study on the use of opioid drugs and the regulations for their use in the 
treatment of non-cancer-related pain in Portugal, given the epidemic that is taking place 
in the United States United. 
The purpose of the interview is to investigate the perceptions and experiences of key 
informants about the use of opioids in Portugal and the regulatory control that governs 
the use of this class of drugs. 
Your participation in this study is entirely voluntary, with the right to refuse the 
interview or cancel your participation at any time during the interview. The interview 
will last 30-40 minutes. In order to accurately record your answers and assist in the 
!112
subsequent analysis of data, we intend to record the interview and for that we request 
your consent. Personal data, such as your name, the position you hold, the position you 
hold, and the institution you belong to will remain anonymous. After 4 months from the 
date of the interview, the recording will be deleted. The collected data will be analyzed 
and published only for academic purposes, in the form of a master's thesis, presentations 
at congresses and publication in scientific journals. 
If you have any questions feel free to ask. After the interview we will remain available 
for any questions that may arise. 
Consent 
I was invited to participate in the study on “The American Opioid Crisis in Public 
Health from a Normative Perspective: Lessons for Portugal”. I read the information 
above and had the opportunity to clarify my doubts. I voluntarily accept to participate in 
this study and consent to the recording in my interview. 
Name of Participant: 
Signature: 
Date: 
I explained the information in this document in detail to the participant and made sure 
that he / she understood that a recorded interview will be conducted. I confirm that the 
participant has had the opportunity to ask questions about the study, and that all 
questions have been answered. I confirm that consent was given voluntarily. 
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A copy of the consent was made available to the participant. 
Researcher's name and signature: 
Date: 
Investigadora: Anna Maria Delios 
Orientadora: Prof. Doutora Paula Lobato de Faria 
Nome da Organização: Escola Nacional Saúde Pública/ Universidade Nova de Lisboa 
(ENSP/UNL) 
Nome do Projeto: A Epidemia Americana do Opióide sob uma Perspetiva Normativa: 
Lições para Portugal 
Informação sobre o estudo 
No âmbito do mestrado em Saúde Pública da ENSP/UNL e sob a orientação da Prof. 
Doutora Paula Lobato de Faria, docente da ENSP/UNL, convido-o a participar num 
estudo sobre o uso de medicamentos opióides e os regulamentos para o seu uso no 
tratamento da dor não relacionada com cancro em Portugal, face à epidemia que 
decorre nos Estados Unidos.  
O objetivo da entrevista é investigar as perceções e experiências de informadores-
chaves sobre o uso de opióides em Portugal e o controle normativo que rege a 
utilização desta classe de medicamentos.  
A sua participação neste estudo é inteiramente voluntária, tendo o direito de recusar a 
entrevista ou cancelar a sua participação em qualquer momento da mesma. A entrevista 
terá uma duração de 30-40 minutos. A fim de registar fidedignamente as suas respostas 
e auxiliar na análise posterior de dados, pretendemos gravar a entrevista e para tal 
solicitamos o seu consentimento. Dados pessoais, como o seu nome, o cargo que ocupa, 
a função que exerce, e a instituição a que pertence permanecerão anônimos. Após 4 
meses da data da entrevista a gravação será apagada. Os dados recolhidos serão 
analisados e publicados apenas para fins académicos, em formato de tese de mestrado, 
apresentações em congressos e publicação em revistas científicas.  
Caso tenha alguma dúvida sinta-se à vontade para perguntar. Após a entrevista 
permaneceremos disponíveis para qualquer questão que possa surgir. 
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Consentimento 
Fui convidado(a) a participar no estudo sobre “A Crise em Saúde Pública Americana 
do Opióide sob uma Perspetiva Normativa: Lições para Portugal”. Li as informações 
acima e tive a oportunidade de esclarecer as minhas dúvidas. Aceito voluntariamente 
participar neste estudo e consinto a gravação na minha entrevista.  
Nome do/a Participante: 
Assinatura: 
Data:  
Expliquei detalhadamente as informações deste documento ao/à participante e 
certifiquei-me de que o/a mesmo(a) entendeu que uma entrevista gravada será 
realizada. Eu confirmo que o/a participante teve a oportunidade de fazer perguntas 
sobre o estudo, e que todas as perguntas foram respondidas. Confirmo que o 
consentimento foi dado voluntariamente. 
Uma cópia do consentimento foi disponibilizada ao participante. 
Nome e assinatura da investigadora:  
Data: 
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